<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIBAVIRIN - ribavirin capsule </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<h1>Ribavirin Capsules<br>200 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_36C3D391-FB8D-44B6-8E0E-A4BBA71354B3"></a><a name="section-1"></a><p></p>
<h1></h1>
<ul>
<li>Ribavirin monotherapy is not effective for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and should not be used alone for this indication. (See <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>).</li>
<li>The primary toxicity of ribavirin is <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. The <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> associated with ribavirin therapy may result in worsening of cardiac disease that has lead to fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. Patients with a history of significant or unstable cardiac disease should not be treated with ribavirin. (See <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>, <a href="#i4i_adverse_effects_ID_08DE82EC-AD40-4EFA-A7D9-EF483E7A5B5F">ADVERSE REACTIONS</a>, and <a href="#i4i_dosage_admin_ID_2D263456-0C32-4883-9FFF-B573B1AE55C1">DOSAGE AND ADMINISTRATION</a>).</li>
<li>Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple-dose half-life of 12 days, and so it may persist in nonplasma compartments for as long as 6 months. Therefore, ribavirin therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of treatment in both female patients and in female partners of male patients who are taking ribavirin therapy. At least two reliable forms of effective contraception must be utilized during treatment and during the 6-month posttreatment follow-up period. (See <a href="#i4i_contraindications_ID_A67E6142-94C4-48F3-A4F1-136F859CCD72">CONTRAINDICATIONS</a>, <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>, <a href="#i4i_precautions_ID_D1BFE763-EC40-43B1-92EA-32C20BA9AD72">PRECAUTIONS</a>: <a href="#i4i_info_patients_ID_9B7F12FC-4BA0-4554-8856-AA3C1BEFF35D">Information for Patients</a> and <a href="#i4i_section_ID_AA86D0EC-DF9C-4386-B7A5-6AD946A64D8E">Pregnancy Category X</a>).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_7776AAAD-33EE-4DF6-98E7-DE88066B296A"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ribavirin is a nucleoside analog. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1<span class="Italics">H</span>-1,2,4-triazole-3-carboxamide and has the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-01.jpg"></div>
<p>Ribavirin is a white, crystalline powder. It is freely soluble in water and slightly soluble in anhydrous alcohol. The empirical formula is C<span class="Sub">8</span>H<span class="Sub">12</span>N<span class="Sub">4</span>O<span class="Sub">5 </span>and the molecular weight is 244.21.</p>
<p>Ribavirin capsules consist of white powder in a white, opaque, gelatin capsule. Each capsule, for oral administration, contains 200 mg ribavirin. In addition, each capsule contains the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, mannitol and povidone. The capsule shell consists of gelatin and titanium dioxide. The capsule is printed with edible blue pharmaceutical ink which is made of FD&amp;C Blue #2 aluminum lake, propylene glycol, shellac and titanium dioxide.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B5220D0C-BA3C-42A2-8B0C-8F371C18DEE7"></a><a name="section-1.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The mechanism of inhibition of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV) RNA by combination therapy with ribavirin and interferon products has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_934EE747-0B0B-4C89-AD4D-1AF1FFF0AAA6"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_081DAFCB-1DCA-4267-9A42-27AA850A02B1"></a><a name="section-2.2"></a><p></p>
<h2>Ribavirin</h2>
<p class="First">Single- and multiple-dose pharmacokinetic properties in adults are summarized in <span class="Bold">TABLE 1</span>. Ribavirin was rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averaged 64% (44%)<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>. There was a linear relationship between dose and AUC<span class="Sub">tf</span> (AUC from time zero to last measurable concentration) following single doses of 200 to 1200 mg ribavirin. The relationship between dose and C<span class="Sub">max </span>was curvilinear, tending to asymptote above single doses of 400 to 600 mg.</p>
<p>Upon multiple oral dosing, based on AUC12<span class="Sub">hr</span>, a sixfold accumulation of ribavirin was observed in plasma. Following oral dosing with 600 mg BID, steady-state was reached by approximately 4 weeks, with mean steady-state plasma concentrations of 2200 (37%) ng/mL. Upon discontinuation of dosing, the mean half-life was 298 (30%) hours, which probably reflects slow elimination from nonplasma compartments.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd><p class="First">In this section of the label, numbers in parenthesis indicate % coefficient of variation.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_32738F1F-4288-45F7-A631-E667D8F8A047"></a><a name="section-2.3"></a><p></p>
<h2>Effect of Food on Absorption of Ribavirin</h2>
<p class="First">Both AUC<span class="Sub">tf </span>and C<span class="Sub">max </span>increased by 70% when ribavirin capsules were administered with a high-fat meal (841 kcal, 53.8 g fat, 31.6 g protein, and 57.4 g carbohydrate) in a single-dose pharmacokinetic study. There are insufficient data to address the clinical relevance of these results. Clinical efficacy studies with ribavirin/INTRON® A (interferon alfa-2b, recombinant) were conducted without instructions with respect to food consumption. During clinical studies with ribavirin/INTRON A, all subjects were instructed to take ribavirin capsules with food. (See <span class="Bold"><a href="#i4i_dosage_admin_ID_2D263456-0C32-4883-9FFF-B573B1AE55C1">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E94DD9E1-609F-4652-804F-A63F96F64382"></a><a name="section-2.4"></a><p></p>
<h2>Effect of Antacid on Absorption of Ribavirin</h2>
<p class="First">Coadministration of ribavirin capsules with an antacid containing magnesium, aluminum, and simethicone (Mylanta®) resulted in a 14% decrease in mean ribavirin AUC<span class="Sub">tf</span>. The clinical relevance of results from this single-dose study is unknown.</p>
<br><a name="ID_47DE1D39-E2FF-4057-9D22-20EE291CE0E3"></a><table border="single" frame="box" width="441.000">
<caption><span>TABLE 1. Mean (% CV) Pharmacokinetic Parameters for Ribavirin Capsules when Administered Individually to Adults</span></caption>
<col width="50.1%">
<col width="23.4%">
<col width="26.5%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>N=11</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>ng/mL</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>ng•hr/mL</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd>data obtained from a single-dose pharmacokinetic study using <span class="Sup">14</span>C labeled ribavirin; N=5</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">¶</a></dt>
<dd>N=6</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">Ribavirin Capsules</span></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Parameter</span></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Single Dose</span></p>
<p><span class="Bold">600 mg</span></p>
<p><span class="Bold">Capsules</span></p>
<span class="Bold">(N=12)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Multiple Dose</span></p>
<p><span class="Bold">600 mg BID</span></p>
<p><span class="Bold">Capsules</span></p>
<span class="Bold">(N=12)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">T<span class="Sub">max</span> (hr)</td>
<td align="center" valign="bottom"> 1.7 (46)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td align="center" valign="bottom"> 3 (60)</td>
</tr>
<tr>
<td align="left" valign="bottom">C<span class="Sub">max</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td align="center" valign="bottom"> 782 (37)</td>
<td align="center" valign="bottom"> 3680 (85)</td>
</tr>
<tr>
<td align="left" valign="bottom">AUC<span class="Sub">tf</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>
</td>
<td align="center" valign="bottom">13400 (48)</td>
<td align="center" valign="bottom">228000 (25)</td>
</tr>
<tr>
<td align="left" valign="bottom">T<span class="Sub">1/2</span> (hr)</td>
<td align="center" valign="bottom"> 43.6 (47)</td>
<td align="center" valign="bottom"> 298 (30)</td>
</tr>
<tr>
<td align="left" valign="bottom">Apparent Volume of Distribution (L)</td>
<td align="center" valign="bottom"> 2825 (9)<a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a>
</td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Apparent Clearance (L/hr)</td>
<td align="center" valign="bottom"> 38.2 (40)</td>
<td align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Absolute Bioavailability</td>
<td class="Botrule" align="center" valign="bottom"> 64% (44)<a name="footnote-reference-6" href="#footnote-6" class="Sup">¶</a>
</td>
<td class="Botrule" align="center" valign="bottom"></td>
</tr>
</tbody>
</table>
<p>Ribavirin transport into nonplasma compartments has been most extensively studied in red blood cells, and has been identified to be primarily via an e<span class="Sub">s</span>-type equilibrative nucleoside transporter. This type of transporter is present on virtually all cell types and may account for the extensive volume of distribution. Ribavirin does not bind to plasma proteins.</p>
<p>Ribavirin has two pathways of metabolism: (i) a reversible phosphorylation pathway in nucleated cells; and (ii) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite. Ribavirin and its triazole carboxamide and triazole carboxylic acid metabolites are excreted renally. After oral administration of 600 mg of <span class="Sup">14</span>C-ribavirin, approximately 61% and 12% of the radioactivity was eliminated in the urine and feces, respectively, in 336 hours. Unchanged ribavirin accounted for 17% of the administered dose.</p>
<p>Results of <span class="Italics">in vitro </span>studies using both human and rat liver microsome preparations indicated little or no cytochrome P450 enzyme-mediated metabolism of ribavirin, with minimal potential for P450 enzyme-based drug interactions.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were noted between INTRON A injection and ribavirin capsules in a multiple-dose pharmacokinetic study.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_9FD0E98C-E595-4B8F-9391-F225ED1E636A"></a><a name="section-2.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Ribavirin has been shown <span class="Italics">in vitro </span>to inhibit phosphorylation of zidovudine and stavudine which could lead to decreased antiretroviral activity. Exposure to didanosine or its active metabolite (dideoxyadenosine 5’-triphosphate) is increased when didanosine is coadministered with ribavirin, which could cause or worsen clinical toxicities (see <span class="Bold"><a href="#i4i_precautions_ID_D1BFE763-EC40-43B1-92EA-32C20BA9AD72">PRECAUTIONS</a>: <a href="#i4i_drug_interaction_ID_5F05D5D0-06C5-4A62-81BD-C894E6D42684">Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_21AD8697-A405-441A-AE4F-A9D4314F80D2"></a><a name="section-2.6"></a><p></p>
<h2>Special Populations</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_5CAF9B3F-104A-4E0E-B244-AC4A455D97EF"></a><a name="section-2.7"></a><p></p>
<h2>Renal Dysfunction</h2>
<p class="First">The pharmacokinetics of ribavirin were assessed after administration of a single oral dose (400 mg) of ribavirin to non HCV-infected subjects with varying degrees of renal dysfunction. The mean AUC<span class="Sub">tf </span>value was threefold greater in subjects with creatinine clearance values between 10 to 30 mL/min when compared to control subjects (creatinine clearance &gt;90 mL/min). In subjects with creatinine clearance values between 30 to 60 mL/min, AUC<span class="Sub">tf </span>was twofold greater when compared to control subjects. The increased AUC<span class="Sub">tf </span>appears to be due to reduction of renal and non-renal clearance in these patients. Phase III efficacy trials included subjects with creatinine clearance values &gt;50 mL/min. The multiple dose pharmacokinetics of ribavirin cannot be accurately predicted in patients with renal dysfunction. Ribavirin is not effectively removed by hemodialysis. Patients with creatinine clearance &lt;50 mL/min should not be treated with ribavirin (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_031EEADA-DA4E-48FB-8A9F-568F929ED242"></a><a name="section-2.8"></a><p></p>
<h2>Hepatic Dysfunction</h2>
<p class="First">The effect of hepatic dysfunction was assessed after a single oral dose of ribavirin (600 mg). The mean AUC<span class="Sub">tf </span>values were not significantly different in subjects with mild, moderate, or severe hepatic dysfunction (Child-Pugh Classification A, B, or C) when compared to control subjects. However, the mean C<span class="Sub">max </span>values increased with severity of hepatic dysfunction and was twofold greater in subjects with severe hepatic dysfunction when compared to control subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E3FD092A-7877-4B64-9852-52FB5BAB4554"></a><a name="section-2.9"></a><p></p>
<h2>Elderly Patients</h2>
<p class="First">Pharmacokinetic evaluations in elderly subjects have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_48C5D431-0DD7-4E1B-BB7B-71810A351456"></a><a name="section-2.10"></a><p></p>
<h2>Gender</h2>
<p class="First">There were no clinically significant pharmacokinetic differences noted in a single-dose study of eighteen male and eighteen female subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_DE13582B-CD39-4A2E-955E-D45525CBAC20"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ribavirin capsules are indicated in combination with INTRON A (interferon alfa-2b, recombinant) Injection for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> in patients 18 years of age and older with compensated liver disease previously untreated with alpha interferon or in patients 18 years of age and older who have relapsed following alpha interferon therapy.</p>
<p>The safety and efficacy of ribavirin capsules with non-pegylated interferons other than the INTRON A product have not been established.</p>
<br><div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_1B086C60-51DE-42A6-9A34-3D58A4C9DA10"></a><a name="section-3.1"></a><p></p>
<h2>Description of Clinical Studies</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_19E826F1-4228-47A0-BD7B-3D3D6B7FAC8F"></a><a name="section-3.2"></a><p></p>
<h2>Ribavirin/INTRON A Combination Therapy</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_833383B9-4247-46AD-8317-45FF0B63F65C"></a><a name="section-3.3"></a><p></p>
<h2>Adult Patients</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0C991748-D829-43EB-8232-36B89C2B80EE"></a><a name="section-3.4"></a><p></p>
<h2>Previously Untreated Patients</h2>
<p class="First">Adults with compensated <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and detectable HCV RNA (assessed by a central laboratory using a research-based RT-PCR assay) who were previously untreated with alpha interferon therapy were enrolled into two multi-center, double-blind trials (US and International) and randomized to receive ribavirin capsules 1200 mg/day (1000 mg/day for patients weighing ≤75 kg) plus INTRON A Injection 3 MIU TIW or INTRON A Injection plus placebo for 24 or 48 weeks followed by 24 weeks of off-therapy follow-up. The International study did not contain a 24-week INTRON A plus placebo treatment arm. The US study enrolled 912 patients who, at baseline, were 67% male, 89% Caucasian with a mean Knodell HAI score (I+II+III) of 7.5, and 72% genotype 1. The International study, conducted in Europe, Israel, Canada, and Australia, enrolled 799 patients (65% male, 95% Caucasian, mean Knodell score 6.8, and 58% genotype 1).</p>
<p>Study results are summarized in <span class="Bold">TABLE 2</span>.</p>
<br><a name="ID_D04E323A-EF4B-4EE0-A490-38EC877E3F0E"></a><table border="single" frame="box" width="599.000">
<caption><span>TABLE 2. Virologic and Histologic Responses: Previously Untreated Patients<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col width="15.9%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Number (%) of patients.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Defined as HCV RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Defined as posttreatment (end of follow-up) minus pretreatment liver biopsy Knodell HAI score (I+II+III) improvement of ≥2 points.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="4" valign="bottom"><span class="Bold">US Study</span></td>
<td class="Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">International Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">24 weeks of</span></p>
<span class="Bold">treatment</span>
</td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=265)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=268)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=266)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Virologic</span></p>
<span class="Bold">Response</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Responder<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td align="center" valign="bottom"> 65 (29)</td>
<td align="center" valign="bottom"> 13 (6)</td>
<td align="center" valign="bottom"> 85 (37)</td>
<td align="center" valign="bottom"> 27 (12)</td>
<td align="center" valign="bottom"> 86 (32)</td>
<td align="center" valign="bottom">113 (42)</td>
<td align="center" valign="bottom"> 46 (17)</td>
</tr>
<tr>
<td align="left" valign="bottom">Nonresponder</td>
<td align="center" valign="bottom">147 (64)</td>
<td align="center" valign="bottom">194 (84)</td>
<td align="center" valign="bottom">110 (48)</td>
<td align="center" valign="bottom">168 (75)</td>
<td align="center" valign="bottom">158 (60)</td>
<td align="center" valign="bottom">120 (45)</td>
<td align="center" valign="bottom">196 (74)</td>
</tr>
<tr>
<td align="left" valign="bottom">Missing Data</td>
<td align="center" valign="bottom"> 16 (7)</td>
<td align="center" valign="bottom"> 24 (10)</td>
<td align="center" valign="bottom"> 33 (14)</td>
<td align="center" valign="bottom"> 30 (13)</td>
<td align="center" valign="bottom"> 21 (8)</td>
<td align="center" valign="bottom"> 35 (13)</td>
<td align="center" valign="bottom"> 24 (9)</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Histologic</span></p>
<span class="Bold">Response</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Improvement<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td align="center" valign="bottom">102 (45)</td>
<td align="center" valign="bottom"> 77 (33)</td>
<td align="center" valign="bottom"> 96 (42)</td>
<td align="center" valign="bottom"> 65 (29)</td>
<td align="center" valign="bottom">103 (39)</td>
<td align="center" valign="bottom">102 (38)</td>
<td align="center" valign="bottom"> 69 (26)</td>
</tr>
<tr>
<td align="left" valign="bottom">No improvement</td>
<td align="center" valign="bottom"> 77 (34)</td>
<td align="center" valign="bottom"> 99 (43)</td>
<td align="center" valign="bottom"> 61 (27)</td>
<td align="center" valign="bottom"> 93 (41)</td>
<td align="center" valign="bottom"> 85 (32)</td>
<td align="center" valign="bottom"> 58 (22)</td>
<td align="center" valign="bottom">111 (41)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Missing Data</td>
<td class="Botrule" align="center" valign="bottom"> 49 (21)</td>
<td class="Botrule" align="center" valign="bottom"> 55 (24)</td>
<td class="Botrule" align="center" valign="bottom"> 71 (31)</td>
<td class="Botrule" align="center" valign="bottom"> 67 (30)</td>
<td class="Botrule" align="center" valign="bottom"> 77 (29)</td>
<td class="Botrule" align="center" valign="bottom">108 (40)</td>
<td class="Botrule" align="center" valign="bottom"> 86 (32)</td>
</tr>
</tbody>
</table>
<br><p>Of patients who had not achieved HCV RNA below the limit of detection of the research based assay by week 24 of ribavirin/INTRON A treatment, less than 5% responded to an additional 24 weeks of combination treatment.</p>
<p>Among patients with HCV Genotype 1 treated with ribavirin/INTRON A therapy who achieved HCV RNA below the detection limit of the research-based assay by 24 weeks, those randomized to 48 weeks of treatment had higher virologic responses compared to those in the 24 week treatment group. There was no observed increase in response rates for patients with HCV nongenotype 1 randomized to ribavirin/INTRON A therapy for 48 weeks compared to 24 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D558A287-F8C6-4C75-975A-6D75FE671CFE"></a><a name="section-3.5"></a><p></p>
<h2>Relapse Patients</h2>
<p class="First">Patients with compensated <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and detectable HCV RNA (assessed by a central laboratory using a research-based RT-PCR assay) who had relapsed following one or two courses of interferon therapy (defined as abnormal serum ALT levels) were enrolled into two multicenter, double-blind trials (US and International) and randomized to receive ribavirin 1200 mg/day (1000 mg/day for patients weighing ≤75 kg) plus INTRON A 3 MIU TIW or INTRON A plus placebo for 24 weeks followed by 24 weeks of off-therapy follow-up. The US study enrolled 153 patients who, at baseline, were 67% male, 92% Caucasian with a mean Knodell HAI score (I+II+III) of 6.8, and 58% genotype 1. The International study, conducted in Europe, Israel, Canada, and Australia, enrolled 192 patients (64% male, 95% Caucasian, mean Knodell score 6.6, and 56% genotype 1).</p>
<p>Study results are summarized in <span class="Bold">TABLE 3</span>.</p>
<a name="ID_67A24B06-D7A8-40AB-8C43-6A28E1C163E2"></a><table border="single" frame="box" width="442.000">
<caption><span>TABLE 3. Virologic and Histologic Responses: Relapse Patients<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></span></caption>
<col width="35.1%">
<col width="16.3%">
<col width="16.3%">
<col width="16.3%">
<col width="16.1%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Number (%) of patients.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>Defined as HCV RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>Defined as posttreatment (end of follow-up) minus pretreatment liver biopsy Knodell HAI score (I+II+III) improvement of ≥2 points.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">US Study</span></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">International Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=76)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=96)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=96)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Virologic</span></p>
Response</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Responder<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a>
</td>
<td align="center" valign="bottom">33 (43)</td>
<td align="center" valign="bottom">3 (4)</td>
<td align="center" valign="bottom">46 (48)</td>
<td align="center" valign="bottom">5 (5)</td>
</tr>
<tr>
<td align="left" valign="bottom">Nonresponder</td>
<td align="center" valign="bottom">36 (47)</td>
<td align="center" valign="bottom">66 (87)</td>
<td align="center" valign="bottom">45 (47)</td>
<td align="center" valign="bottom">91 (95)</td>
</tr>
<tr>
<td align="left" valign="bottom">Missing Data</td>
<td align="center" valign="bottom">8 (10)</td>
<td align="center" valign="bottom">7 (9)</td>
<td align="center" valign="bottom">5 (5)</td>
<td align="center" valign="bottom">0 (0)</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Histologic</span></p>
<span class="Bold">Response</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Improvement<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a>
</td>
<td align="center" valign="bottom">38 (49)</td>
<td align="center" valign="bottom">27 (36)</td>
<td align="center" valign="bottom">49 (51)</td>
<td align="center" valign="bottom">30 (31)</td>
</tr>
<tr>
<td align="left" valign="bottom">No improvement</td>
<td align="center" valign="bottom">23 (30)</td>
<td align="center" valign="bottom">37 (49)</td>
<td align="center" valign="bottom">29 (30)</td>
<td align="center" valign="bottom">44 (46)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Missing Data</td>
<td class="Botrule" align="center" valign="bottom">16 (21)</td>
<td class="Botrule" align="center" valign="bottom">12 (16)</td>
<td class="Botrule" align="center" valign="bottom">18 (19)</td>
<td class="Botrule" align="center" valign="bottom">22 (23)</td>
</tr>
</tbody>
</table>
<p>Virologic and histologic responses were similar among male and female patients in both the previously untreated and relapse studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_A67E6142-94C4-48F3-A4F1-136F859CCD72"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A1957739-B020-4E77-BA50-A77C1724B909"></a><a name="section-4.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Ribavirin capsules may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>, <a href="#i4i_precautions_ID_D1BFE763-EC40-43B1-92EA-32C20BA9AD72">PRECAUTIONS</a>: <a href="#i4i_info_patients_ID_9B7F12FC-4BA0-4554-8856-AA3C1BEFF35D">Information for Patients</a></span> and <span class="Bold"><a href="#i4i_section_ID_AA86D0EC-DF9C-4386-B7A5-6AD946A64D8E">Pregnancy Category X</a></span>).</p>
<p>Ribavirin capsules are contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ribavirin or any component of the capsule.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span> must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> worse.</p>
<p>Patients with hemoglobinopathies (e.g., <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> major, sickle-cell <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) should not be treated with ribavirin capsules.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Based on results of clinical trials ribavirin monotherapy is not effective for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; therefore, ribavirin capsules must not be used alone. The safety and efficacy of ribavirin capsules with non-pegylated interferons other than INTRON A product have not been established.</p>
<p>There are significant adverse events caused by ribavirin/INTRON A therapy, including severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span> or attempts occurred more frequently among pediatric patients, primarily adolescents, compared to adult patients (2.4% versus 1%) during treatment and off-therapy follow-up. <span class="Underline">The Appendix to this package insert should be reviewed in its entirety prior to initiation of therapy of ribavirin capsules taken together with INTRON A for additional safety information.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7B175623-B6FF-4B81-9048-4D3FB5EF07F4"></a><a name="section-5.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Ribavirin capsules may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the exposed fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin capsules have demonstrated significant teratogenic and/or embryocidal effects in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin. RIBAVIRIN THERAPY SHOULD NOT BE STARTED UNTIL A REPORT OF A <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">NEGATIVE PREGNANCY TEST</span> HAS BEEN OBTAINED IMMEDIATELY PRIOR TO PLANNED INITIATION OF THERAPY. Patients should be instructed to use at least two forms of effective contraception during treatment and during the six month period after treatment has been stopped based on multiple dose half-life of ribavirin of 12 days. Pregnancy testing should occur monthly during ribavirin therapy and for six months after therapy has stopped (see <a href="#i4i_contraindications_ID_A67E6142-94C4-48F3-A4F1-136F859CCD72">CONTRAINDICATIONS</a> and <a href="#i4i_precautions_ID_D1BFE763-EC40-43B1-92EA-32C20BA9AD72">PRECAUTIONS</a>: <a href="#i4i_info_patients_ID_9B7F12FC-4BA0-4554-8856-AA3C1BEFF35D">Information for Patients</a> and <a href="#i4i_section_ID_AA86D0EC-DF9C-4386-B7A5-6AD946A64D8E">Pregnancy Category X</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_5CD20A74-71CA-420A-A8D9-7E14A18A6A51"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></h2>
<p class="First"><span class="Bold">The primary toxicity of ribavirin is <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, which was observed in approximately 10% of ribavirin/INTRON A-treated patients in clinical trials (see <a href="#i4i_adverse_effects_ID_08DE82EC-AD40-4EFA-A7D9-EF483E7A5B5F">ADVERSE REACTIONS</a>: <a href="#i4i_section_ID_7D4DDFC8-26AF-477D-8FE1-C27623D8AC90">Laboratory Values</a>: </span><span class="Bold"><span class="Italics"><a href="#i4i_section_ID_46F8D8CB-5E33-4E50-9FF0-866AA12530E1">Hemoglobin</a></span></span><span class="Bold">). The <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> associated with ribavirin capsules occurs within 1 to 2 weeks of initiation of therapy. BECAUSE THE INITIAL DROP IN HEMOGLOBIN MAY BE SIGNIFICANT, IT IS ADVISED THAT HEMOGLOBIN OR HEMATOCRIT BE OBTAINED PRETREATMENT AND AT WEEK 2 AND WEEK 4 OF THERAPY, OR MORE FREQUENTLY IF CLINICALLY INDICATED. Patients should then be followed as clinically appropriate.</span></p>
<p><span class="Bold">Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> have been reported in patients with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> caused by ribavirin. Patients should be assessed for underlying cardiac disease before initiation of ribavirin therapy. Patients with pre-existing cardiac disease should have electrocardiograms administered before treatment, and should be appropriately monitored during therapy. If there is any deterioration of cardiovascular status, therapy should be suspended or discontinued. (See <a href="#i4i_dosage_admin_ID_2D263456-0C32-4883-9FFF-B573B1AE55C1">DOSAGE AND ADMINISTRATION</a>: Guidelines for Dose Modification). Because cardiac disease may be worsened by drug induced <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, patients with a history of significant or unstable cardiac disease should not use ribavirin. (See <a href="#i4i_adverse_effects_ID_08DE82EC-AD40-4EFA-A7D9-EF483E7A5B5F">ADVERSE REACTIONS</a>).</span></p>
<p>Ribavirin and INTRON A therapy should be suspended in patients with signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and discontinued in patients with confirmed <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p>Ribavirin should not be used in patients with creatinine clearance &lt;50 mL/min. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_section_ID_21AD8697-A405-441A-AE4F-A9D4314F80D2">Special Populations</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A8758537-A4B3-41E2-B052-E53503944119"></a><a name="section-5.3"></a><p></p>
<h2>Pulmonary</h2>
<p class="First">Pulmonary symptoms, including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, have been reported during therapy with ribavirin/INTRON A; occasional cases of fatal <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> have occurred. In addition, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> or the exacerbation of <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> has been reported. If there is evidence of pulmonary infiltrates or <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary function impairment</span>, the patient should be closely monitored, and if appropriate, combination ribavirin/INTRON A treatment should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_C3954E09-4E33-4604-BF95-EA2995B5CD8C"></a><a name="section-5.4"></a><p></p>
<h2>Dental and Periodontal Disorders</h2>
<p class="First">Dental and periodontal disorders have been reported in patients receiving ribavirin and interferon combination therapy. In addition, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of ribavirin capsules and interferon alfa-2b. Patients should brush their teeth thoroughly twice daily and have regular dental examinations. In addition, some patients may experience <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. If this reaction occurs, they should be advised to rinse out their mouth thoroughly afterwards.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_D1BFE763-EC40-43B1-92EA-32C20BA9AD72"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The safety and efficacy of ribavirin/INTRON A therapy for the treatment of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, adenovirus, RSV, parainfluenza, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have not been established. Ribavirin capsules should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered.</p>
<p>The safety and efficacy of ribavirin/INTRON A therapy has not been established in liver or other organ transplant patients, patients with decompensated liver disease due to <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, patients who are nonresponders to interferon therapy, or patients coinfected with HBV or HIV.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_9B7F12FC-4BA0-4554-8856-AA3C1BEFF35D"></a><a name="section-6.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients must be informed that ribavirin capsules may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the exposed fetus. Ribavirin must not be used by women who are pregnant or by men whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking ribavirin. Ribavirin should not be initiated until a report of a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> has been obtained immediately prior to initiation of therapy. Patients must perform a pregnancy test monthly during therapy and for 6 months posttherapy. Women of childbearing potential must be counseled about use of effective contraception (two reliable forms) prior to initiating therapy. Patients (male and female) must be advised of the teratogenic/embryocidal risks and must be instructed to practice effective contraception during ribavirin and for 6 months posttherapy. Patients (male and female) should be advised to notify the physician immediately in the event of a pregnancy. (See <span class="Bold"><a href="#i4i_contraindications_ID_A67E6142-94C4-48F3-A4F1-136F859CCD72">CONTRAINDICATIONS</a></span>and <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>).</p>
<p>If pregnancy does occur during treatment or during 6 months posttherapy, the patient must be advised of the teratogenic risk of ribavirin therapy to the fetus. Patients, or partners of patients, should immediately report any pregnancy that occurs during treatment or within 6 months after treatment cessation to their physician. Physicians should report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214.</p>
<p>Patients receiving ribavirin capsules should be informed of the benefits and risks associated with treatment, directed in its appropriate use, and referred to the patient <span class="Bold">MEDICATION GUIDE</span> for ribavirin capsules. Patients should be informed that the effect of treatment of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> on transmission is not known, and that appropriate precautions to prevent transmission of the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus should be taken.</p>
<p>The most common adverse experience occurring with ribavirin capsules is <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, which may be severe. (See <span class="Bold"><a href="#i4i_adverse_effects_ID_08DE82EC-AD40-4EFA-A7D9-EF483E7A5B5F">ADVERSE REACTIONS</a></span>). Patients should be advised that laboratory evaluations are required prior to starting therapy and periodically thereafter. (See <span class="Bold"><a href="#i4i_lab_tests_ID_CD564859-758C-459E-8133-16C645405640">Laboratory Tests</a></span>). It is advised that patients be well hydrated, especially during the initial stages of treatment.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_ID_CD564859-758C-459E-8133-16C645405640"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The following laboratory tests are recommended for all patients treated with ribavirin capsules, prior to beginning treatment and then periodically thereafter.</p>
<ul>
<li>Standard hematologic tests – including hemoglobin (pretreatment, week 2 and week 4 of therapy, and as clinically appropriate [see <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>]), complete and differential white blood cell counts, and platelet count.</li>
<li>Blood chemistries – liver function tests and TSH.</li>
<li>Pregnancy – including monthly monitoring for women of childbearing potential.</li>
<li>ECG (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_0D88B1E7-F5A5-4B2E-934F-F32419A6B2F1"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis and Mutagenesis</h2>
<p class="First">Ribavirin did not cause an increase in any tumor type when administered for 6 months in the transgenic p53 deficient mouse model at doses up to 300 mg/kg (estimated human equivalent of 25 mg/kg based on body surface area adjustment for a 60 kg adult; approximately 1.9 times the maximum recommended human daily dose). Ribavirin was non-carcinogenic when administered for 2 years to rats at doses up to 40 mg/kg (estimated human equivalent of 5.71 mg/kg based on body surface area adjustment for a 60 kg adult). However, this dose was less than the maximum tolerated dose, and therefore the study was not adequate to fully characterize the carcinogenic potential of ribavirin.</p>
<p>Ribavirin demonstrated increased incidences of mutation and cell transformation in multiple genotoxicity assays. Ribavirin was active in the Balb/3T3 <span class="Italics">In Vitro </span>Cell Transformation Assay. Mutagenic activity was observed in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and at doses of 20 to 200 mg/kg (estimated human equivalent of 1.67 to 16.7 mg/kg, based on body surface area adjustment for a 60 kg adult; 0.1 to 1 times the maximum recommended human 24-hour dose of ribavirin) in a mouse micronucleus assay. A dominant lethal assay in rats was negative, indicating that if mutations occurred in rats they were not transmitted through male gametes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_54EA13FA-16F4-48FE-9E63-E18AE2B5B0D8"></a><a name="section-6.4"></a><p></p>
<h2>Impairment of Fertility</h2>
<p class="First">Ribavirin demonstrated significant embryocidal and/or teratogenic effects at doses well below the recommended human dose in all animal species in which adequate studies have been conducted.</p>
<p>Fertile women and partners of fertile women should not receive ribavirin unless the patient and his/her partner are using effective contraception (two reliable forms). Based on a multiple dose half-life(t<span class="Sub">1/2</span>) of ribavirin of 12 days, effective contraception must be utilized for 6 months posttherapy (e.g., 15 half-lives of clearance for ribavirin).</p>
<p>Ribavirin should be used with caution in fertile men. In studies in mice to evaluate the time course and reversibility of ribavirin-induced testicular degeneration at doses of 15 to 150 mg/kg/day (estimated human equivalent of 1.25 to 12.5 mg/kg/day, based on body surface area adjustment for a 60 kg adult; 0.1 to 0.8 times the maximum human 24-hour dose of ribavirin) administered for 3 or 6 months, abnormalities in sperm occurred. Upon cessation of treatment, essentially total recovery from ribavirin-induced testicular toxicity was apparent within 1 or 2 spermatogenesis cycles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_37E9A1C5-20BC-48C0-9330-F7A92537E0C5"></a><a name="section-6.5"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First">Long-term studies in the mouse and rat (18 to 24 months; doses of 20 to 75 and 10 to 40 mg/kg/day, respectively {estimated human equivalent doses of 1.67 to 6.25 and 1.43 to 5.71 mg/kg/day, respectively, based on body surface area adjustment for a 60 kg adult; approximately 0.1 to 0.4 times the maximum human 24-hour dose of ribavirin}) have demonstrated a relationship between chronic ribavirin exposure and increased incidences of vascular lesions (microscopic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>) in mice. In rats, <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> occurred in controls, but the incidence was increased in ribavirin-treated rats.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_AA86D0EC-DF9C-4386-B7A5-6AD946A64D8E"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy Category X</h2>
<p class="First">(See <span class="Bold"><a href="#i4i_contraindications_ID_A67E6142-94C4-48F3-A4F1-136F859CCD72">CONTRAINDICATIONS</a></span>.)</p>
<p>Ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton, and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with escalation of the drug dose. Survival of fetuses and offspring was reduced. In conventional embryotoxicity/<span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies in rats and rabbits, observed no effect dose levels were well below those for proposed clinical use (0.3 mg/kg/day for both the rat and rabbit; approximately 0.06 times the recommended human 24-hour dose of ribavirin). No maternal toxicity or effects on offspring were observed in a peri/postnatal toxicity study in rats dosed orally at up to 1 mg/kg/day (estimated human equivalent dose of 0.17 mg/kg based on body surface area adjustment for a 60 kg adult; approximately 0.01 times the maximum recommended human 24-hour dose of ribavirin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_496717CD-DB12-4F37-B834-837564CF2683"></a><a name="section-6.7"></a><p></p>
<h2>Treatment and Posttreatment</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_514800A5-AB24-4D7A-B872-96807D158BBD"></a><a name="section-6.8"></a><p></p>
<h2>Potential Risk to the Fetus</h2>
<p class="First">Ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. It is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. In a study in rats, it was concluded that dominant lethality was not induced by ribavirin at doses up to 200 mg/kg for 5 days (estimated human equivalent doses of 7.14 to 28.6 mg/kg, based on body surface area adjustment for a 60 kg adult; up to 1.7 times the maximum recommended human dose of ribavirin). However, because of the potential human teratogenic effects of ribavirin, male patients should be advised to take every precaution to avoid risk of pregnancy for their female partners.</p>
<p>Women of childbearing potential should not receive ribavirin unless they are using effective contraception (two reliable forms) during the therapy period. In addition, effective contraception should be utilized for 6 months post-therapy based on a multiple-dose half-life (t<span class="Sub">1/2</span>) of ribavirin of 12 days.</p>
<p>Male patients and their female partners must practice effective contraception (two reliable forms) during treatment with ribavirin and for the 6-month post-therapy period (e.g., 15 half-lives for ribavirin clearance from the body).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_51CAAC44-6916-4056-9DE7-5CADFAA78A67"></a><a name="section-6.9"></a><p></p>
<h2>Ribavirin Pregnancy Registry</h2>
<p class="First"><span class="Bold">A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment and for six months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_9214E188-BC91-4557-BC94-30DA419C85D2"></a><a name="section-6.10"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether the ribavirin product is excreted in human milk. Because of the potential for serious adverse reactions from the drug in nursing infants, a decision should be made whether to discontinue nursing or to delay or discontinue ribavirin capsules.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_5EE617B2-A175-40F4-B352-F8A0BBA0346A"></a><a name="section-6.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ribavirin/INTRON A therapy did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects.</p>
<p>Ribavirin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients often have decreased renal function, care should be taken in dose selection. Renal function should be monitored and dosage adjustments should be made accordingly. Ribavirin should not be used in patients with creatinine clearance &lt;50 mL/min. (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>).</p>
<p>In general, ribavirin capsules should be administered to elderly patients cautiously, starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic and/or cardiac function, and of concomitant disease or other drug therapy. In clinical trials, elderly subjects had a higher frequency of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (67%) than did younger patients (28%) (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_73E27E2D-FCC1-4C7A-92B5-775E5D014534"></a><a name="section-6.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span> or attempts occurred more frequently among pediatric patients, primarily adolescents, compared to adult patients (2.4% versus 1%) during treatment and off-therapy follow-up (see <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>).</span> As in adult patients, pediatric patients experienced other psychiatric adverse events (eg, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (see <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>). During a 48-week course of therapy there was a decrease in the rate of linear growth (mean percentile assignment decrease of 9%) and a decrease in the rate of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (mean percentile assignment decrease of 13%). A general reversal of these trends was noted during the 24-week post-treatment period.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_5F05D5D0-06C5-4A62-81BD-C894E6D42684"></a><a name="section-6.13"></a><p></p>
<h2>Drug Interactions</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_EE9C0647-045F-42F8-836D-94D9523A4834"></a><a name="section-6.14"></a><p></p>
<h2>Didanosine</h2>
<p class="First">Co-administration of ribavirin capsules and didanosine is not recommended. Reports of fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, as well as <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and symptomatic hyperlactactemia/<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have been reported in clinical trials (see <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_drug_interaction_ID_9FD0E98C-E595-4B8F-9391-F225ED1E636A">Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_4F527199-A8E4-44AF-A1FA-E66B399029C4"></a><a name="section-6.15"></a><p></p>
<h2>Stavudine and Zidovudine</h2>
<p class="First">Ribavirin may antagonize the <span class="Italics">in vitro</span> antiviral activity of stavudine and zidovudine against HIV. Therefore, concomitant use of ribavirin with either of these drugs should be used with caution (see <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_drug_interaction_ID_9FD0E98C-E595-4B8F-9391-F225ED1E636A">Drug Interactions</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_08DE82EC-AD40-4EFA-A7D9-EF483E7A5B5F"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">The primary toxicity of ribavirin is <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. Reductions in hemoglobin levels occurred within the first 1 to 2 weeks of oral therapy. (See <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>). Cardiac and pulmonary events associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occurred in approximately 10% of patients (See <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a>).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_40528F75-F62A-4B67-A012-E6D1676E4695"></a><a name="section-7.1"></a><p></p>
<h2>Ribavirin/INTRON A Combination Therapy</h2>
<p class="First">In clinical trials, 19% and 6% of previously untreated and relapse patients, respectively, discontinued therapy due to adverse events in the combination arms compared to 13% and 3% in the interferon arms. Selected treatment-emergent adverse events that occurred in the US studies with ≥5% incidence are provided in <span class="Bold">TABLE 4 </span>by treatment group. In general, the selected treatment-emergent adverse events were reported with lower incidence in the international studies as compared to the US studies with the exception of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<br><a name="ID_541B7003-4420-457E-BE78-31A0CBDFACCE"></a><table border="single" frame="box" width="623.000">
<caption><span>TABLE 4. Selected Treatment-Emergent Adverse Events: Previously Untreated and Relapse Adult Patients</span></caption>
<col width="30.7%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Patients reporting one or more adverse events. A patient may have reported more than one adverse event within a body system/organ class category.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="6" valign="bottom"><span class="Bold">Percentage of Patients</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="4" valign="bottom"><span class="Bold">US Previously Untreated Study</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">US Relapse Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Patients Reporting</span></p>
<span class="Bold">Adverse Events<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=76)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Application Site Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span></td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">12</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom"> 8</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span></td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 3</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Body as a Whole </span>–</p>
<span class="Bold">General Disorders</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="bottom">63</td>
<td align="center" valign="bottom">63</td>
<td align="center" valign="bottom">66</td>
<td align="center" valign="bottom">67</td>
<td align="center" valign="bottom">66</td>
<td align="center" valign="bottom">68</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="bottom">68</td>
<td align="center" valign="bottom">62</td>
<td align="center" valign="bottom">70</td>
<td align="center" valign="bottom">72</td>
<td align="center" valign="bottom">60</td>
<td align="center" valign="bottom">53</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td align="center" valign="bottom">40</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">42</td>
<td align="center" valign="bottom">39</td>
<td align="center" valign="bottom">43</td>
<td align="center" valign="bottom">37</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center" valign="bottom">37</td>
<td align="center" valign="bottom">35</td>
<td align="center" valign="bottom">41</td>
<td align="center" valign="bottom">40</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">36</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">18</td>
<td align="center" valign="bottom">18</td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom">13</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom"> 7</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Central &amp; Peripheral</span></p>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">15</td>
<td align="center" valign="bottom">23</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom">26</td>
<td align="center" valign="bottom">21</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Gastrointestinal System Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="bottom">38</td>
<td align="center" valign="bottom">35</td>
<td align="center" valign="bottom">46</td>
<td align="center" valign="bottom">33</td>
<td align="center" valign="bottom">47</td>
<td align="center" valign="bottom">33</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom">14</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom"> 9</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="center" valign="bottom">11</td>
<td class="Botrule" align="center" valign="bottom">10</td>
<td class="Botrule" align="center" valign="bottom"> 9</td>
<td class="Botrule" align="center" valign="bottom">13</td>
<td class="Botrule" align="center" valign="bottom">12</td>
<td class="Botrule" align="center" valign="bottom"> 8</td>
</tr>
</tbody>
</table>
<br><a name="ID_0807E463-3F96-4448-8D95-8FEC39762AAE"></a><table border="single" frame="box" width="623.000">
<caption><span>TABLE 4. Selected Treatment-Emergent Adverse Events: Previously Untreated and Relapse Adult Patients (continued)</span></caption>
<col width="30.7%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Patients reporting one or more adverse events. A patient may have reported more than one adverse event within a body system/organ class category.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="6" valign="bottom"><span class="Bold">Percentage of Patients</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="4" valign="bottom"><span class="Bold">US Previously Untreated Study</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">US Relapse Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Patients Reporting</span></p>
<span class="Bold">Adverse Events<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a></span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<span class="Bold">(N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=76)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Musculoskeletal System Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="bottom">61</td>
<td align="center" valign="bottom">57</td>
<td align="center" valign="bottom">64</td>
<td align="center" valign="bottom">63</td>
<td align="center" valign="bottom">61</td>
<td align="center" valign="bottom">58</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" valign="bottom">30</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">33</td>
<td align="center" valign="bottom">36</td>
<td align="center" valign="bottom">29</td>
<td align="center" valign="bottom">29</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">26</td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">22</td>
<td align="center" valign="bottom">28</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="bottom">39</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">39</td>
<td align="center" valign="bottom">30</td>
<td align="center" valign="bottom">26</td>
<td align="center" valign="bottom">25</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td align="center" valign="bottom">23</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">20</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">36</td>
<td align="center" valign="bottom">37</td>
<td align="center" valign="bottom">23</td>
<td align="center" valign="bottom">14</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional lability</span></td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom">11</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom">12</td>
<td align="center" valign="bottom"> 8</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Concentration impaired</span></td>
<td align="center" valign="bottom">11</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">18</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">12</td>
<td align="center" valign="bottom"> 7</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Skin and Appendages Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">26</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 5</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Special Senses, Other Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td class="Botrule" align="center" valign="bottom"> 7</td>
<td class="Botrule" align="center" valign="bottom"> 4</td>
<td class="Botrule" align="center" valign="bottom"> 8</td>
<td class="Botrule" align="center" valign="bottom"> 4</td>
<td class="Botrule" align="center" valign="bottom"> 6</td>
<td class="Botrule" align="center" valign="bottom"> 5</td>
</tr>
</tbody>
</table>
<br><p>In addition, the following spontaneous adverse events have been reported during the marketing surveillance of ribavirin/INTRON A therapy: hearing disorder and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7D4DDFC8-26AF-477D-8FE1-C27623D8AC90"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Values</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9AC2A0E3-7EA9-467E-ACA3-4009EA8AA723"></a><a name="section-7.3"></a><p></p>
<h2>Ribavirin/INTRON A Combination Therapy</h2>
<p class="First">Changes in selected hematologic values (hemoglobin, white blood cells, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, and platelets)during therapy are described below. (See <span class="Bold">TABLE 5</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_46F8D8CB-5E33-4E50-9FF0-866AA12530E1"></a><a name="section-7.4"></a><p></p>
<h2>Hemoglobin</h2>
<p class="First">Hemoglobin decreases among patients receiving ribavirin therapy began at Week 1, with stabilization by Week 4. In previously untreated patients treated for 48 weeks, the mean maximum decrease from baseline was 3.1 g/dL in the US study and 2.9 g/dL in the International study. In relapse patients, the mean maximum decrease from baseline was 2.8 g/dL in the US study and 2.6 g/dL in the international study. Hemoglobin values returned to pretreatment levels within 4 to 8 weeks of cessation of therapy in most patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B759DD8D-7727-462F-934D-1FC84E2F357F"></a><a name="section-7.5"></a><p></p>
<h2>Bilirubin and Uric Acid</h2>
<p class="First">Increases in both bilirubin and uric acid, associated with <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, were noted in clinical trials. Most were moderate biochemical changes and were reversed within 4 weeks after treatment discontinuation. This observation occurs most frequently in patients with a previous diagnosis of Gilbert’s syndrome. This has not been associated with hepatic dysfunction or clinical morbidity.</p>
<br><a name="ID_421BB6FF-0C38-4EC6-95D1-CB556929DAFE"></a><table border="single" frame="box" width="875.000">
<caption><span>TABLE 5. Selected Hematologic Values During Treatment with Ribavirin Capsules plus INTRON A: Previously Untreated and Relapse Adult Patients</span></caption>
<col width="15.0%">
<col width="15.1%">
<col width="13.7%">
<col width="15.1%">
<col width="13.7%">
<col width="14.4%">
<col width="13.0%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="6" valign="bottom"><span class="Bold">Percentage of Patients</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="4" valign="bottom"><span class="Bold">US Previously Untreated Study</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">US Relapse Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Ribavirin (N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Placebo (N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Ribavirin (N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Placebo (N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Ribavirin (N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Placebo (N=76)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">Hemoglobin (g/dL)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">9.5-10.9</td>
<td align="center" valign="bottom"> 24</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom"> 32</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 3</td>
</tr>
<tr>
<td align="left" valign="bottom">8.0-9.4</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">6.5-7.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;6.5</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">Leukocytes (x10<span class="Sup">9</span>/L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">2.0-2.9</td>
<td align="center" valign="bottom"> 40</td>
<td align="center" valign="bottom"> 20</td>
<td align="center" valign="bottom"> 38</td>
<td align="center" valign="bottom"> 23</td>
<td align="center" valign="bottom">45</td>
<td align="center" valign="bottom">26</td>
</tr>
<tr>
<td align="left" valign="bottom">1.5-1.9</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 3</td>
</tr>
<tr>
<td align="left" valign="bottom">1.0-1.4</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;1.0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (x10<span class="Sup">9</span>/L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">1.0-1.49</td>
<td align="center" valign="bottom"> 30</td>
<td align="center" valign="bottom"> 32</td>
<td align="center" valign="bottom"> 31</td>
<td align="center" valign="bottom"> 44</td>
<td align="center" valign="bottom">42</td>
<td align="center" valign="bottom">34</td>
</tr>
<tr>
<td align="left" valign="bottom">0.75-0.99</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 15</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom">18</td>
</tr>
<tr>
<td align="left" valign="bottom">0.5-0.74</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;0.5</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 8</td>
</tr>
<tr>
<td align="left" valign="bottom">Platelets (x10<span class="Sup">9</span>/L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">70-99</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td align="left" valign="bottom">50-69</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 3</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 3</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 5</td>
</tr>
<tr>
<td align="left" valign="bottom">30-49</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;30</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">Total Bilirubin (mg/dL)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">1.5-3.0</td>
<td align="center" valign="bottom"> 27</td>
<td align="center" valign="bottom"> 13</td>
<td align="center" valign="bottom"> 32</td>
<td align="center" valign="bottom"> 13</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 7</td>
</tr>
<tr>
<td align="left" valign="bottom">3.1-6.0</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 3</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">6.1-12.0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">&gt;12.0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
</tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_2119E73F-A97D-446B-9280-7A9D03DA0A93"></a><a name="section-7.6"></a><p></p>
<h2>Postmarketing Experiences</h2>
<p class="First">The following adverse reactions have been identified during the post approval use of ribavirin capsules in combination with INTRON A: hearing disorder, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_B9B179C8-6BC6-4CC2-B659-7A61A803B566"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Bold">There is limited experience with overdosage. Acute ingestion of up to 20 grams of ribavirin capsules, INTRON A ingestion of up to 120 million units, and subcutaneous doses of INTRON A up to 10 times the recommended doses have been reported. Primary effects that have been observed are increased incidence and severity of the adverse events related to the therapeutic use of INTRON A and ribavirin. However, hepatic enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported with administration of single subcutaneous doses of INTRON A that exceed dosing recommendations.</span></p>
<p>There is no specific antidote for INTRON A or ribavirin, and hemodialysis and peritoneal dialysis are not effective treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of either agent.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_2D263456-0C32-4883-9FFF-B573B1AE55C1"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">(See <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_section_ID_21AD8697-A405-441A-AE4F-A9D4314F80D2">Special Populations</a>; see <a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_5179AAD7-BD0C-47A3-898E-B82B875CD39A"></a><a name="section-9.1"></a><p></p>
<h2>Ribavirin/INTRON A Combination Therapy</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_03F26C88-599E-47CF-9016-551F63664C18"></a><a name="section-9.2"></a><p></p>
<h2>Adults</h2>
<p class="First">The recommended dose of ribavirin capsules in patients 18 years of age and older depends on the patient’s body weight. The recommended dose of ribavirin is provided in <span class="Bold">TABLE 6</span>.</p>
<p>The recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. The duration of treatment should be individualized to the patient depending on baseline disease characteristics, response to therapy, and tolerability of the regimen. (See <span class="Bold"><a href="#i4i_section_ID_1B086C60-51DE-42A6-9A34-3D58A4C9DA10">Description of Clinical Studies</a></span> and <span class="Bold"><a href="#i4i_adverse_effects_ID_08DE82EC-AD40-4EFA-A7D9-EF483E7A5B5F">ADVERSE REACTIONS</a></span>). After 24 weeks of treatment, virologic response should be assessed. Treatment discontinuation should be considered in any patient who has not achieved an HCV RNA below the limit of detection of the assay by 24 weeks. There are no safety and efficacy data on treatment for longer than 48 weeks in the previously untreated patient population.</p>
<p>In patients who relapse following non-pegylated interferon mono-therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in the relapse patient population.</p>
<br><a name="ID_2C6769CD-1098-4B9F-8021-4F9DC2817F28"></a><table border="single" frame="box" width="442.000">
<caption><span>TABLE 6. Recommended Dosing for Patients 18 years of age and older</span></caption>
<col width="50.0%">
<col width="50.0%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold">Body Weight</span></td>
<td class="Toprule" align="left" valign="bottom"><span class="Bold">Ribavirin Capsules</span></td>
</tr>
<tr>
<td align="left" valign="bottom"><p class="First">≤75 kg</p></td>
<td align="left" valign="bottom">
<p class="First">2 x 200 mg capsules AM,</p>
<p>3 x 200 mg capsules PM</p>
daily p.o.</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><p class="First">&gt;75 kg</p></td>
<td class="Botrule" align="left" valign="bottom">
<p class="First">3 x 200 mg capsules AM,</p>
<p>3 x 200 mg capsules PM</p>
daily p.o.</td>
</tr>
</tbody>
</table>
<p>Ribavirin may be administered without regard to food, but should be administered in a consistent manner with respect to food intake. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71">CLINICAL PHARMACOLOGY</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_89585641-CCC9-43DD-A70B-F83601B581A7"></a><a name="section-9.3"></a><p></p>
<h2>Dose Modifications</h2>
<p class="First">(See <span class="Bold">TABLE 7</span>.)</p>
<p>If severe adverse reactions or laboratory abnormalities develop during combination ribavirin/INTRON A therapy the dose should be modified, or discontinued if appropriate, until the adverse reactions abate. If intolerance persists after dose adjustment, ribavirin/INTRON A therapy should be discontinued.</p>
<p>Ribavirin should not be used in patients with creatinine clearance &lt;50 mL/min. Subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and/or those over the age of 50 should be carefully monitored with respect to development of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>and <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_D3F95C61-51FE-4754-B4C5-888EAD9FCA71">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_section_ID_21AD8697-A405-441A-AE4F-A9D4314F80D2">Special Populations</a></span>).</p>
<p>Ribavirin should be administered with caution to patients with pre-existing cardiac disease. Patients should be assessed before commencement of therapy and should be appropriately monitored during therapy. If there is any deterioration of cardiovascular status, therapy should be stopped. (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>).</p>
<p>For patients with a history of stable cardiovascular disease, a permanent dose reduction is required if the hemoglobin decreases by ≥2 g/dL during any 4-week period. In addition, for these cardiac history patients, if the hemoglobin remains &lt;12 g/dL after 4 weeks on a reduced dose, the patient should discontinue combination ribavirin/INTRON A therapy.</p>
<p>It is recommended that a patient whose hemoglobin level <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 10 g/dL have his/her ribavirin dose reduced to 600 mg daily (1 x 200 mg capsule AM, 2 x 200 mg capsules PM) for adults. A patient whose hemoglobin level <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 8.5 g/dL should be permanently discontinued from ribavirin therapy. (See <span class="Bold"><a href="#i4i_warnings_ID_2C7DA16D-E234-4B59-9865-E67EE7499DA8">WARNINGS</a></span>).</p>
<br><a name="ID_70BA889D-BD70-424B-B077-54693106E6C4"></a><table border="single" frame="box" width="441.000">
<caption><span>TABLE 7. Guidelines for Dose Modifications and Discontinuation for <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></caption>
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Dose Reduction</span></p>
<p><span class="Bold">Ribavirin –</span></p>
<span class="Bold">600 mg daily adults</span>
</td>
<td class="Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Permanent</span></p>
<p><span class="Bold">Discontinuation of</span></p>
<span class="Bold">Ribavirin Treatment</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">Hemoglobin </td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">No Cardiac History </span></td>
<td align="center" valign="bottom">&lt;<span class="Bold">10 g/dL</span>
</td>
<td align="center" valign="bottom">&lt;<span class="Bold">8.5 g/dL</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><p class="First"><span class="Bold">Cardiac History Patients</span></p></td>
<td class="Botrule" align="center" valign="bottom">
<p class="First"><span class="Bold">≥2 g/dL decrease</span></p>
<p><span class="Bold">during any 4-week</span></p>
<span class="Bold">period during treatment</span>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">&lt;<span class="Bold">12 g/dL after</span></p>
<p><span class="Bold">4 weeks dose</span></p>
<span class="Bold">reduction</span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_73F7808F-35E8-4FC1-8C73-2CA79EFBF062"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ribavirin capsules, 200 mg are white, opaque, hard gelatin capsules imprinted (in blue) RIBAVIRIN over 200 mg on cap and GG 608 on body, and are supplied as follows:</p>
<p>NDC 0781-2043-42 in bottles of 42 capsules</p>
<p>NDC 0781-2043-16 in bottles of 56 capsules</p>
<p>NDC 0781-2043-67 in bottles of 70 capsules</p>
<p>NDC 0781-2043-04 in bottles of 84 capsules</p>
<p>NDC 0781-2043-01 in bottles of 100 capsules</p>
<p>NDC 0781-2043-28 in bottles of 168 capsules</p>
<p>NDC 0781-2043-10 in bottles of 1000 capsules</p>
<p>NDC 0781-2043-13 in unit dose packages of 100 capsules</p>
<p>Dispense in a tight container as defined in the USP.</p>
<p>Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_6433F72C-D28A-4976-93F2-EA96F9B397EF"></a><a name="section-11"></a><p></p>
<h1>APPENDIX to Package Insert (Information on Ribavirin Capsules taken together with INTRON A)</h1>
<p class="First"><span class="Bold">[Note: In addition to REBETOL® (ribavirin) Capsules, Schering Corporation also markets REBETRON®. REBETRON is a copackaged combination therapy containing REBETOL (ribavirin, USP) and INTRON A (interferon alfa-2b, recombinant) Injection. REBETRON has a package insert that provides information on the combination use of REBETOL (ribavirin, USP) and INTRON A. This Appendix provides information on ribavirin capsules taken together with INTRON A that corresponds to information in the package insert for REBETRON.] </span></p>
<br><div class="Warning">
<a name="ID_FBF52857-9EFA-4A94-88C4-6DF303E52F11"></a><a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">CONTRAINDICATIONS AND WARNINGS</span></p>
<p><span class="Bold">Combination ribavirin capsules/INTRON A therapy is contraindicated in females who are pregnant and in the male partners of females who are pregnant. Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of treatment in female patients, and in female partners of male patients who are taking combination ribavirin capsules/INTRON A therapy. Females of childbearing potential and males must use two reliable forms of effective contraception during treatment and during the 6-month posttreatment follow-up period. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species studied. See <a href="#i4i_contraindications_ID_8C649737-6D26-4CCD-930E-89571B019518">CONTRAINDICATIONS</a> and <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>.</span></p>
<p><span class="Bold">Ribavirin capsules monotherapy is not effective for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and should not be used for this indication. See <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>.</span></p>
<p><span class="Bold">Alpha interferons, including INTRON A, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping INTRON A therapy. See <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>and <a href="#i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331">ADVERSE REACTIONS</a>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_BE7D616A-1D84-4770-B158-DB474AF71AB9"></a><a name="section-12"></a><p></p>
<h1>DESCRIPTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8298F0CC-07AC-4CC6-AEF6-BBBBC0CE316F"></a><a name="section-12.1"></a><p></p>
<h2>Ribavirin Capsules</h2>
<p class="First">Ribavirin is a nucleoside analog with antiviral activity. The chemical name of ribavirin is 1-β-D-ribofuranosyl-1<span class="Italics">H</span>-1,2,4-triazole-3-carboxamide and has the following structural formula:</p>
<p>Ribavirin is a white, crystalline powder. It is freely soluble in water and slightly soluble in anhydrous alcohol. The molecular formula is C<span class="Sub">8</span>H<span class="Sub">12</span>N<span class="Sub">4</span>O<span class="Sub">5 </span>and the molecular weight is 244.21.</p>
<p>Ribavirin capsules consist of white powder in a white, opaque, gelatin capsule. Each capsule, for oral administration, contains 200 mg ribavirin. In addition, each capsule contains the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, mannitol and povidone. The capsule shell consists of gelatin and titanium dioxide. The capsule is printed with edible blue pharmaceutical ink which is made of FD&amp;C Blue #2 aluminum lake, propylene glycol, shellac and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_162E9C42-5F9F-45D5-BC4A-4B54E6F0DB79"></a><a name="section-12.2"></a><p></p>
<h2>INTRON A</h2>
<p class="First">INTRON A is Schering Corporation’s brand name for interferon alfa-2b, recombinant, a purified, sterile, recombinant interferon product.</p>
<p>Interferon alfa-2b, recombinant has been classified as an alpha interferon and is a water-soluble protein composed of 165 amino acids with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Escherichia coli</span> bearing a genetically engineered plasmid containing an interferon alfa-2b gene from human leukocytes. The fermentation is carried out in a defined nutrient medium containing the antibiotic tetracycline hydrochloride at a concentration of 5 to 10 mg/L; the presence of this antibiotic is not detectable in the final product.</p>
<p>INTRON A Injection is a clear, colorless solution. The 3 million IU vial of INTRON A Injection contains 3 million IU of interferon alfa-2b, recombinant per 0.5 mL. The 18 million IU multidose vial of INTRON A Injection contains a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL (3 million IU/0.5 mL) in order to provide the delivery of six 0.5 mL doses, each containing 3 million IU of INTRON A (for a label strength of 18 million IU). The 18 million IU INTRON A Injection multidose pen contains a total of 22.5 million IU of interferon alfa-2b, recombinant per 1.5 mL (3 million IU/0.2 mL) in order to provide the delivery of six 0.2-mL doses, each containing 3 million IU of INTRON A (for a label strength of 18 million IU). Each mL also contains 7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol as a preservative.</p>
<p>Based on the specific activity of approximately 2.6 x 10<span class="Sup">8 </span> IU/mg protein as measured by HPLC assay, the corresponding quantities of interferon alfa-2b, recombinant in the vials and pen described above are approximately 0.012 mg, 0.088 mg, and 0.087 mg protein, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_701B2D07-209E-48C3-B4E3-C248BDB51CEF"></a><a name="section-12.3"></a><p></p>
<h2>Mechanism of Action</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_4F5B99CF-2909-4498-BDF5-3010302F4CDA"></a><a name="section-12.4"></a><p></p>
<h2>Ribavirin/Interferon alfa-2b, recombinant</h2>
<p class="First">The mechanism of inhibition of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV) RNA by combination therapy with ribavirin capsules and INTRON A has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_8BB60E0F-79C2-420E-8BAE-3222275F292C"></a><a name="section-13"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E78A2EA6-D3D6-4A0E-AA17-C59D8AF74C92"></a><a name="section-13.1"></a><p></p>
<h2>Pharmacokinetics</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_16E78A68-4E7F-4CBF-B8F0-86259C037201"></a><a name="section-13.2"></a><p></p>
<h2>Interferon alfa-2b, recombinant</h2>
<p class="First">Single- and multiple-dose pharmacokinetic properties of INTRON A (interferon alfa-2b, recombinant) are summarized in <span class="Bold">TABLE 1</span>. Following a single 3 million IU (MIU) subcutaneous dose in 12 patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>, mean (% CV<a name="footnote-reference-15" href="#footnote-15" class="Sup">2</a>) serum concentrations peaked at 7 (44%) hours. Following 4 weeks of subcutaneous dosing with 3 MIU three times a week (TIW), interferon serum concentrations were undetectable predose. However, a twofold increase in bioavailability was noted upon multiple dosing of interferon; the reason for this is unknown. Mean half-life values following single- and multiple-dose administrations were 6.8 (24%) hours and 6.5 (29%) hours, respectively.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">2</a></dt>
<dd><p class="First">In this section of the label, numbers in parenthesis indicate % coefficient of variation.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A9D73423-092A-440C-AFD3-8F58D0CC5FC5"></a><a name="section-13.3"></a><p></p>
<h2>Ribavirin</h2>
<p class="First">Single- and multiple-dose pharmacokinetic properties in adults with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> are summarized in <span class="Bold">TABLE 1</span>. Ribavirin was rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averaged 64% (44%). There was a linear relationship between dose and AUC<span class="Sub">tf </span> (AUC from time zero to last measurable concentration) following single doses of 200 to 1200 mg ribavirin. The relationship between dose and C<span class="Sub">max </span>was curvilinear, tending to asymptote above single doses of 400 to 600 mg.</p>
<p>Upon multiple oral dosing, based on AUC12<span class="Sub">hr</span>, a sixfold accumulation of ribavirin was observed in plasma. Following oral dosing with 600 mg BID, steady-state was reached by approximately 4 weeks, with mean steady-state plasma concentrations of 2200 (37%) ng/mL. Upon discontinuation of dosing, the mean half-life was 298 (30%) hours, which probably reflects slow elimination from nonplasma compartments.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_14F2CF63-0AC1-4F2B-8374-CCEFF72BE9D3"></a><a name="section-13.4"></a><p></p>
<h2>Effect of Food on Absorption of Ribavirin</h2>
<p class="First">Both AUC<span class="Sub">tf </span>and C<span class="Sub">max </span>increased by 70% when ribavirin capsules were administered with a high-fat meal (841 kcal, 53.8 g fat, 31.6 g protein, and 57.4 g carbohydrate) in a single-dose pharmacokinetic study. There are insufficient data to address the clinical relevance of these results. Clinical efficacy studies were conducted without instructions with respect to food consumption. (See <span class="Bold"><a href="#i4i_dosage_admin_ID_DFAFA8B6-5782-47DE-A5D9-F602EFF9A399">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E79B307A-0736-4E8D-B7DD-0E95907DF49E"></a><a name="section-13.5"></a><p></p>
<h2>Effect of Antacid on Absorption of Ribavirin</h2>
<p class="First">Coadministration with an antacid containing magnesium, aluminum, and simethicone (Mylanta®) resulted in a 14% decrease in mean ribavirin AUC<span class="Sub">tf</span>. The clinical relevance of results from this single-dose study is unknown.</p>
<br><a name="ID_499E1225-730B-4383-8A8E-C69EA1E997CA"></a><table border="single" frame="box" width="442.000">
<caption><span>TABLE 1. Mean (% CV) Pharmacokinetic Parameters for INTRON A and RIBAVIRIN CAPSULES When Administered Individually to Adults with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></span></caption>
<col width="28.3%">
<col width="16.3%">
<col width="16.3%">
<col width="20.4%">
<col width="18.8%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>N=11</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>IU/mL for INTRON A and ng/mL for RIBAVIRIN CAPSULES</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">‡</a></dt>
<dd>IU•hr/mL for INTRON A and ng•hr/mL for RIBAVIRIN CAPSULES</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">§</a></dt>
<dd>data obtained from a single-dose pharmacokinetic study using <span class="Sup">14</span>C labeled ribavirin; N=5</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">¶</a></dt>
<dd>N=6</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">INTRON A (N=12)</span></td>
<td class="Toprule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Ribavirin Capsules</span></p>
<span class="Bold">(N=12)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Parameter</span></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Single</span></p>
<p><span class="Bold">Dose</span></p>
<span class="Bold">3 MIU</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Multiple</span></p>
<p><span class="Bold">Dose</span></p>
<p><span class="Bold">3 MIU</span></p>
<span class="Bold">TIW</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Single</span></p>
<p><span class="Bold">Dose</span></p>
<span class="Bold">600 mg</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">Multiple</span></p>
<p><span class="Bold">Dose</span></p>
<span class="Bold">600 mg BID</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">T<span class="Sub">max</span> (hr)</td>
<td align="center" valign="bottom"> 7 (44)</td>
<td align="center" valign="bottom"> 5 (37)</td>
<td align="center" valign="bottom"> 1.7 (46)<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</td>
<td align="center" valign="bottom"> 3 (60)</td>
</tr>
<tr>
<td align="left" valign="bottom">C<span class="Sub">max</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a>
</td>
<td align="center" valign="bottom">13.9 (32)</td>
<td align="center" valign="bottom">29.7 (33)</td>
<td align="center" valign="bottom"> 782 (37)</td>
<td align="center" valign="bottom"> 3680 (85)</td>
</tr>
<tr>
<td align="left" valign="bottom">AUC<span class="Sub">tf</span><a name="footnote-reference-18" href="#footnote-18" class="Sup">‡</a>
</td>
<td align="center" valign="bottom"> 142 (43)</td>
<td align="center" valign="bottom"> 333 (39)</td>
<td align="center" valign="bottom">13400 (48)</td>
<td align="center" valign="bottom">228000 (25)</td>
</tr>
<tr>
<td align="left" valign="bottom">T<span class="Sub">1/2</span> (hr)</td>
<td align="center" valign="bottom"> 6.8 (24)</td>
<td align="center" valign="bottom"> 6.5 (29)</td>
<td align="center" valign="bottom"> 43.6 (47)</td>
<td align="center" valign="bottom"> 298 (30)</td>
</tr>
<tr>
<td align="left" valign="bottom"> Apparent</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"> Volume of</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"> Distribution (L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"> 2825 (9)<a name="footnote-reference-19" href="#footnote-19" class="Sup">§</a>
</td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First">Apparent</p>
 Clearance (L/hr)</td>
<td align="center" valign="bottom">14.3 (17)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"> 38.2 (40)</td>
<td align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">
<p class="First">Absolute</p>
 Bioavailability</td>
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"> 64% (44)<a name="footnote-reference-20" href="#footnote-20" class="Sup">¶</a>
</td>
<td class="Botrule" align="center" valign="bottom"></td>
</tr>
</tbody>
</table>
<p>Ribavirin transport into nonplasma compartments has been most extensively studied in red blood cells, and has been identified to be primarily via an e<span class="Sub">s</span>-type equilibrative nucleoside transporter. This type of transporter is present on virtually all cell types and may account for the extensive volume of distribution. Ribavirin does not bind to plasma proteins.</p>
<p>Ribavirin has two pathways of metabolism: (i) a reversible phosphorylation pathway in nucleated cells; and (ii) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite. Ribavirin and its triazole carboxamide and triazole carboxylic acid metabolites are excreted renally. After oral administration of 600 mg of <span class="Sup">14</span>C-ribavirin, approximately 61% and 12% of the radioactivity was eliminated in the urine and feces, respectively, in 336 hours. Unchanged ribavirin accounted for 17% of the administered dose.</p>
<p>Results of <span class="Italics">in vitro </span>studies using both human and rat liver microsome preparations indicated little or no cytochrome P450 enzyme-mediated metabolism of ribavirin, with minimal potential for P450 enzyme-based drug interactions.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were noted between INTRON A Injection and ribavirin capsules in a multiple-dose pharmacokinetic study.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_EDA77A27-0215-4980-B63B-3AD65489A98E"></a><a name="section-13.6"></a><p></p>
<h2>Special Populations</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D8229F66-8810-43CE-8AA7-FF05134DED56"></a><a name="section-13.7"></a><p></p>
<h2>Renal Dysfunction</h2>
<p class="First">The pharmacokinetics of ribavirin were assessed after administration of a single oral dose (400 mg) of ribavirin to subjects with varying degrees of renal dysfunction. The mean AUC<span class="Sub">tf </span>value was threefold greater in subjects with creatinine clearance values between 10 to 30 mL/min when compared to control subjects (creatinine clearance &gt;90 mL/min). This appears to be due to reduction of apparent clearance in these patients. Ribavirin was not removed by hemodialysis. Patients with creatinine clearance &lt; 50 mL/min should not be treated with ribavirin capsules (see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_CA6AD345-B539-4D14-B814-FA01D9BF2DFF"></a><a name="section-13.8"></a><p></p>
<h2>Hepatic Dysfunction</h2>
<p class="First">The effect of hepatic dysfunction was assessed after a single oral dose of ribavirin (600 mg). The mean AUC<span class="Sub">tf </span>values were not significantly different in subjects with mild, moderate, or severe hepatic dysfunction (Child-Pugh Classification A, B, or C), when compared to control subjects. However, the mean C<span class="Sub">max </span>values increased with severity of hepatic dysfunction and was twofold greater in subjects with severe hepatic dysfunction when compared to control subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D2FE09E2-3632-4228-B8C0-EB01324EB298"></a><a name="section-13.9"></a><p></p>
<h2>Elderly Patients</h2>
<p class="First">Pharmacokinetic evaluations for elderly subjects have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B2D7E631-C61A-4E67-AF21-8FD4923D0F72"></a><a name="section-13.10"></a><p></p>
<h2>Gender</h2>
<p class="First">There were no clinically significant pharmacokinetic differences noted in a single-dose study of eighteen male and eighteen female subjects.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_7C1FCFED-D2F6-49F2-91FF-E26572D9AFC0"></a><a name="section-13.11"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Ribavirin has been shown <span class="Italics">in vitro </span>to inhibit phosphorylation of zidovudine and stavudine which could lead to decreased antiretroviral activity. Exposure to didanosine or its active metabolite (dideoxyadenosine 5’-triphosphate) is increased when didanosine is coadministered with ribavirin, which could cause or worsen clinical toxicities (see <span class="Bold"><a href="#i4i_precautions_ID_9ED1678B-FBEE-4E88-B9D5-18C9682715A2">PRECAUTIONS</a>: <a href="#i4i_drug_interaction_ID_D4E0450D-F32A-45CD-B8E5-1D6448F173D3">Drug Interactions</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_8C7FF400-6977-4D78-867A-85F859800A85"></a><a name="section-14"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ribavirin capsules are indicated in combination with INTRON A (interferon alfa-2b, recombinant) Injection for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> in patients 18 years of age and older with compensated liver disease previously untreated with alpha interferon or in patients 18 years of age and older who have relapsed following alpha interferon therapy.</p>
<p>The safety and efficacy of ribavirin capsules with non-pegylated interferons other than the INTRON A product have not been established.</p>
<br><div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_52859A16-7321-44BE-AE65-0079A0119248"></a><a name="section-14.1"></a><p></p>
<h2>Description of Clinical Studies</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_00A4C930-A537-48DB-95B4-55FD6CECBAB6"></a><a name="section-14.2"></a><p></p>
<h2>Previously Untreated Patients</h2>
<p class="First">Adults with compensated <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and detectable HCV RNA (assessed by a central laboratory using a research-based RT-PCR assay) who were previously untreated with alpha interferon therapy were enrolled into two multicenter, double-blind trials (US and International) and randomized to receive ribavirin capsules 1200 mg/day (1000 mg/day for patients weighing ≤75 kg) plus INTRON A Injection 3 MIU TIW or INTRON A Injection plus placebo for 24 or 48 weeks followed by 24 weeks of off-therapy follow-up. The International study did not contain a 24-week INTRON A plus placebo treatment arm. The US study enrolled 912 patients who, at baseline, were 67% male, 89% caucasian with a mean Knodell HAI score (I+II+III) of 7.5, and 72% genotype 1. The International study, conducted in Europe, Israel, Canada, and Australia, enrolled 799 patients (65% male, 95% caucasian, mean Knodell score 6.8, and 58% genotype 1).</p>
<p>Study results are summarized in <span class="Bold">TABLE 2</span>.</p>
<br><a name="ID_17C5A5CA-F6FD-46DD-BCFF-96C3177DEB7C"></a><table border="single" frame="box" width="599.000">
<caption><span>TABLE 2. Virologic and Histologic Responses: Previously Untreated Patients<a name="footnote-reference-21" href="#footnote-21" class="Sup">*</a></span></caption>
<col width="15.9%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-21" href="#footnote-reference-21">*</a></dt>
<dd>Number (%) of patients.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">†</a></dt>
<dd>Defined as HCV RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">‡</a></dt>
<dd>Defined as posttreatment (end of follow-up) minus pretreatment liver biopsy Knodell HAI score (I+II+III) improvement of ≥2 points.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="4" valign="bottom"><span class="Bold">US Study</span></td>
<td class="Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">International Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">24 weeks of</span></p>
<span class="Bold">treatment</span>
</td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=265)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=268)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=266)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Virologic</span></p>
<span class="Bold">Response</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Responder<a name="footnote-reference-22" href="#footnote-22" class="Sup">†</a>
</td>
<td align="center" valign="bottom"> 65 (29)</td>
<td align="center" valign="bottom"> 13 (6)</td>
<td align="center" valign="bottom"> 85 (37)</td>
<td align="center" valign="bottom"> 27 (12)</td>
<td align="center" valign="bottom"> 86 (32)</td>
<td align="center" valign="bottom">113 (42)</td>
<td align="center" valign="bottom"> 46 (17)</td>
</tr>
<tr>
<td align="left" valign="bottom">Nonresponder</td>
<td align="center" valign="bottom">147 (64)</td>
<td align="center" valign="bottom">194 (84)</td>
<td align="center" valign="bottom">110 (48)</td>
<td align="center" valign="bottom">168 (75)</td>
<td align="center" valign="bottom">158 (60)</td>
<td align="center" valign="bottom">120 (45)</td>
<td align="center" valign="bottom">196 (74)</td>
</tr>
<tr>
<td align="left" valign="bottom">Missing Data</td>
<td align="center" valign="bottom"> 16 (7)</td>
<td align="center" valign="bottom"> 24 (10)</td>
<td align="center" valign="bottom"> 33 (14)</td>
<td align="center" valign="bottom"> 30 (13)</td>
<td align="center" valign="bottom"> 21 (8)</td>
<td align="center" valign="bottom"> 35 (13)</td>
<td align="center" valign="bottom"> 24 (9)</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Histologic</span></p>
<span class="Bold">Response</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Improvement<a name="footnote-reference-23" href="#footnote-23" class="Sup">‡</a>
</td>
<td align="center" valign="bottom">102 (45)</td>
<td align="center" valign="bottom"> 77 (33)</td>
<td align="center" valign="bottom"> 96 (42)</td>
<td align="center" valign="bottom"> 65 (29)</td>
<td align="center" valign="bottom">103 (39)</td>
<td align="center" valign="bottom">102 (38)</td>
<td align="center" valign="bottom"> 69 (26)</td>
</tr>
<tr>
<td align="left" valign="bottom">No improvement</td>
<td align="center" valign="bottom"> 77 (34)</td>
<td align="center" valign="bottom"> 99 (43)</td>
<td align="center" valign="bottom"> 61 (27)</td>
<td align="center" valign="bottom"> 93 (41)</td>
<td align="center" valign="bottom"> 85 (32)</td>
<td align="center" valign="bottom"> 58 (22)</td>
<td align="center" valign="bottom">111 (41)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Missing Data</td>
<td class="Botrule" align="center" valign="bottom"> 49 (21)</td>
<td class="Botrule" align="center" valign="bottom"> 55 (24)</td>
<td class="Botrule" align="center" valign="bottom"> 71 (31)</td>
<td class="Botrule" align="center" valign="bottom"> 67 (30)</td>
<td class="Botrule" align="center" valign="bottom"> 77 (29)</td>
<td class="Botrule" align="center" valign="bottom">108 (40)</td>
<td class="Botrule" align="center" valign="bottom"> 86 (32)</td>
</tr>
</tbody>
</table>
<br><p>Of patients who had not achieved HCV RNA below the limit of detection of the research based assay by week 24 of ribavirin capsules/INTRON A treatment, less than 5% responded to an additional 24 weeks of combination treatment.</p>
<p>Among patients with HCV genotype 1 treated with ribavirin capsules/INTRON A therapy who achieved HCV RNA below the detection limit of the research-based assay by 24 weeks, those randomized to 48 weeks of treatment had higher virologic responses compared to those in the 24-week treatment group. There was no observed increase in response rates for patients with HCV nongenotype 1 randomized to ribavirin capsules/INTRON A therapy for 48 weeks compared to 24 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7ADFCF34-3C68-4DBB-9A33-0522CBBEC414"></a><a name="section-14.3"></a><p></p>
<h2>Relapse Patients</h2>
<p class="First">Patients with compensated <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and detectable HCV RNA (assessed by a central laboratory using a research based RT-PCR assay) who had relapsed following one or two courses of interferon therapy (defined as abnormal serum ALT levels) were enrolled into two multicenter, double-blind trials (US and International) and randomized to receive ribavirin capsules 1200 mg/day (1000 mg/day for patients weighing ≤75 kg) plus INTRON A 3 MIU TIW or INTRON A plus placebo for 24 weeks followed by 24 weeks of off-therapy follow-up. The US study enrolled 153 patients who, at baseline, were 67% male, 92% caucasian with a mean Knodell HAI score (I+II+III) of 6.8, and 58% genotype 1. The International study, conducted in Europe, Israel, Canada, and Australia, enrolled 192 patients (64% male, 95% caucasian, mean Knodell score 6.6, and 56% genotype 1).</p>
<p>Study results are summarized in <span class="Bold">TABLE 3</span>.</p>
<br><a name="ID_44923104-7F8F-481F-A5E2-A8BD0242CD73"></a><table border="single" frame="box" width="442.000">
<caption><span>TABLE 3. Virologic and Histologic Responses: Relapse Patients<a name="footnote-reference-24" href="#footnote-24" class="Sup">*</a></span></caption>
<col width="35.1%">
<col width="16.3%">
<col width="16.3%">
<col width="16.3%">
<col width="16.1%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-24" href="#footnote-reference-24">*</a></dt>
<dd>Number (%) of patients.</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">†</a></dt>
<dd>Defined as HCV RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">‡</a></dt>
<dd>Defined as posttreatment (end of follow-up) minus pretreatment liver biopsy Knodell HAI score (I+II+III) improvement of ≥2 points.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">US Study</span></td>
<td class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">International Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=76)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=96)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=96)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Virologic</span></p>
Response</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Responder<a name="footnote-reference-25" href="#footnote-25" class="Sup">†</a>
</td>
<td align="center" valign="bottom">33 (43)</td>
<td align="center" valign="bottom">3 (4)</td>
<td align="center" valign="bottom">46 (48)</td>
<td align="center" valign="bottom">5 (5)</td>
</tr>
<tr>
<td align="left" valign="bottom">Nonresponder</td>
<td align="center" valign="bottom">36 (47)</td>
<td align="center" valign="bottom">66 (87)</td>
<td align="center" valign="bottom">45 (47)</td>
<td align="center" valign="bottom">91 (95)</td>
</tr>
<tr>
<td align="left" valign="bottom">Missing Data</td>
<td align="center" valign="bottom">8 (10)</td>
<td align="center" valign="bottom">7 (9)</td>
<td align="center" valign="bottom">5 (5)</td>
<td align="center" valign="bottom">0 (0)</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Histologic</span></p>
<span class="Bold">Response</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">Improvement<a name="footnote-reference-26" href="#footnote-26" class="Sup">‡</a>
</td>
<td align="center" valign="bottom">38 (49)</td>
<td align="center" valign="bottom">27 (36)</td>
<td align="center" valign="bottom">49 (51)</td>
<td align="center" valign="bottom">30 (31)</td>
</tr>
<tr>
<td align="left" valign="bottom">No improvement</td>
<td align="center" valign="bottom">23 (30)</td>
<td align="center" valign="bottom">37 (49)</td>
<td align="center" valign="bottom">29 (30)</td>
<td align="center" valign="bottom">44 (46)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Missing Data</td>
<td class="Botrule" align="center" valign="bottom">16 (21)</td>
<td class="Botrule" align="center" valign="bottom">12 (16)</td>
<td class="Botrule" align="center" valign="bottom">18 (19)</td>
<td class="Botrule" align="center" valign="bottom">22 (23)</td>
</tr>
</tbody>
</table>
<p>Virologic and histologic responses were similar among male and female patients in both the previously untreated and relapse studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_8C649737-6D26-4CCD-930E-89571B019518"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Combination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. <span class="Bold">See boxed CONTRAINDICATIONS AND WARNINGS. See <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>.</span></p>
<p>Ribavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ribavirin and/or alpha interferon or any component of the capsule and/or injection.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span> must not be treated with combination ribavirin capsules/INTRON A therapy.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57"></a><a name="section-16"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_783592C1-442A-4A20-B1C1-F0627A467FCB"></a><a name="section-16.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Category X, may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. See boxed CONTRAINDICATIONS AND WARNINGS. See <a href="#i4i_contraindications_ID_8C649737-6D26-4CCD-930E-89571B019518">CONTRAINDICATIONS</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7E4228C7-1327-4DA1-BDF6-E07352AD3A7E"></a><a name="section-16.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">HEMOLYTIC ANEMIA</span> (HEMOGLOBIN &lt;10 G/DL) WAS OBSERVED IN APPROXIMATELY 10% OF RIBAVIRIN CAPSULES/INTRON A-TREATED PATIENTS IN CLINICAL TRIALS (See <a href="#i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331">ADVERSE REACTIONS</a>: <a href="#i4i_section_ID_7D4DDFC8-26AF-477D-8FE1-C27623D8AC90">Laboratory Values</a>:</span><span class="Bold"><span class="Italics"><a href="#i4i_section_ID_FEADF610-6F81-4C3E-AC9F-7458F2863351">Hemoglobin</a></span></span><span class="Bold">). <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">ANEMIA</span> OCCURRED WITHIN 1 TO 2 WEEKS OF INITIATION OF RIBAVIRIN THERAPY. BECAUSE OF THIS INITIAL ACUTE DROP IN HEMOGLOBIN, IT IS ADVISED THAT COMPLETE BLOOD COUNTS (CBC) SHOULD BE OBTAINED PRETREATMENT AND AT WEEK 2 AND WEEK 4 OF THERAPY OR MORE FREQUENTLY IF CLINICALLY INDICATED. PATIENTS SHOULD THEN BE FOLLOWED AS CLINICALLY APPROPRIATE.</span></p>
<p>The <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> associated with ribavirin capsules/INTRON A therapy may result in deterioration of cardiac function and/or exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span>. Patients should be assessed before initiation of therapy and should be appropriately monitored during therapy. If there is any deterioration of cardiovascular status, therapy should be suspended or discontinued. (See <a href="#i4i_dosage_admin_ID_DFAFA8B6-5782-47DE-A5D9-F602EFF9A399">DOSAGE AND ADMINISTRATION</a>.) Because cardiac disease may be worsened by drug induced <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, patients with a history of significant or unstable cardiac disease should not use combination ribavirin capsules/INTRON A therapy. (See <span class="Bold"><a href="#i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331">ADVERSE REACTIONS</a></span>.)</p>
<p>Similarly, patients with hemoglobinopathies (e.g., <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span>, sickle-cell <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) should not be treated with combination ribavirin capsules/INTRON A therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_EE36E029-262A-4677-A4A4-0BEF91AD699A"></a><a name="section-16.3"></a><p></p>
<h2>Psychiatric</h2>
<p class="First"><span class="Bold">Severe psychiatric adverse events, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, psychoses, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behavior</span> (<span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, suicidal attempts, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span>) and rare instances of <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">homicidal ideation</span> have occurred during combination ribavirin capsules/Intron A therapy, both in patients with and without a previous psychiatric disorder. Ribavirin capsules/Intron A therapy should be used with extreme caution in patients with a history of pre-existing psychiatric disorders, and all patients should be carefully monitored for evidence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>.</span></p>
<p><span class="Bold">Suspension of ribavirin capsules/Intron A therapy should be considered if psychiatric intervention and/or dose reduction is unsuccessful in controlling <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>. In severe cases, therapy should be stopped immediately and psychiatric intervention sought. (See <a href="#i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331">ADVERSE REACTIONS</a>.)</span></p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F3EE942B-4C3A-420D-A702-68D1090AD3A0"></a><a name="section-16.4"></a><p></p>
<h2>Bone Marrow Toxicity</h2>
<p class="First">INTRON A therapy suppresses bone marrow function and may result in severe <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> including very rare events of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>. It is advised that complete blood counts (CBC) be obtained pretreatment and monitored routinely during therapy (see <span class="Bold"><a href="#i4i_precautions_ID_9ED1678B-FBEE-4E88-B9D5-18C9682715A2">PRECAUTIONS</a>: <a href="#i4i_lab_tests_ID_5C1470FB-A1EC-47D5-90A7-22B278E8069F">Laboratory Tests</a></span>). INTRON A therapy should be discontinued in patients who develop severe decreases in neutrophil (&lt;0.5 x 10<span class="Sup">9</span>/L) or platelet counts (&lt;25 x 10<span class="Sup">9</span>/L) (see <span class="Bold"><a href="#i4i_dosage_admin_ID_DFAFA8B6-5782-47DE-A5D9-F602EFF9A399">DOSAGE AND ADMINISTRATION</a>: Guidelines for Dose Modifications</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8D659CB3-18D4-47ED-BEAE-E43737A9031E"></a><a name="section-16.5"></a><p></p>
<h2>Pulmonary</h2>
<p class="First">Pulmonary symptoms, including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, have been reported during therapy with ribavirin capsules/INTRON A; occasional cases of fatal <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> have occurred. In addition, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> or the exacerbation of <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> has been reported. If there is evidence of pulmonary infiltrates or <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary function impairment</span>, the patient should be closely monitored, and if appropriate, combination ribavirin capsules/INTRON A treatment should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_31E46B7B-6345-407F-8B87-4BF7CEDD9D90"></a><a name="section-16.6"></a><p></p>
<h2>Other</h2>
<ul>
<li>Ribavirin capsules monotherapy is not effective for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and should not be used for this indication.</li>
<li>Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> has been observed in patients treated with ribavirin capsules/INTRON A therapy. Ribavirin capsules/INTRON A therapy should be suspended in patients with signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and discontinued in patients with confirmed <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</li>
<li>Combination ribavirin capsules/INTRON A therapy should not be used in patients with creatinine clearance &lt;50 mL/min.</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been observed in patients treated with INTRON A.</li>
<li>Ophthalmologic disorders have been reported with treatment with alpha interferons (including INTRON A therapy). Investigators using alpha interferons have reported the occurrence of <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhages</span>, <span class="product-label-link" type="condition" conceptid="4220027" conceptname="Cotton wool spots">cotton wool spots</span>, and retinal artery or vein obstruction in rare instances. Any patient complaining of loss of visual acuity or visual field should have an eye examination. Because these ocular events may occur in conjunction with other disease states, a visual exam prior to initiation of combination ribavirin capsules/INTRON A therapy is recommended in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</li>
<li>Acute serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (eg, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) have been observed in INTRON A-treated patients; if such an acute reaction develops, combination ribavirin capsules/INTRON A therapy should be discontinued immediately and appropriate medical therapy instituted.</li>
<li>Combination ribavirin capsules/INTRON A therapy should be discontinued for patients developing thyroid abnormalities during treatment whose thyroid function cannot be controlled by medication.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_9ED1678B-FBEE-4E88-B9D5-18C9682715A2"></a><a name="section-17"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Exacerbation of autoimmune disease has been reported in patients receiving alpha interferon therapy (including INTRON A therapy). Ribavirin capsules/INTRON A therapy should be used with caution in patients with other <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span>.</p>
<p>There have been reports of interferon, including INTRON A (interferon alfa-2b, recombinant) exacerbating pre-existing <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>; therefore, combination ribavirin capsules/INTRON A therapy should be used in these patients only if the potential benefit justifies the potential risk.</p>
<p>The safety and efficacy of ribavirin capsules/INTRON A therapy has not been established in liver or other organ transplant patients, decompensated <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C patients, patients who are nonresponders to interferon therapy, or patients coinfected with HBV or HIV.</p>
<p>The safety and efficacy of ribavirin capsules monotherapy for the treatment of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, adenovirus, early RSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, parainfluenza, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> have not been established and ribavirin capsules should not be used for these indications.</p>
<p>There is no information regarding the use of ribavirin capsules with other interferons.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_32484E8A-E206-4004-9ED0-22A344736F04"></a><a name="section-17.1"></a><p></p>
<h2>Triglycerides</h2>
<p class="First">Elevated triglyceride levels have been observed in patients treated with interferon including ribavirin capsules/INTRON A therapy. Elevated triglyceride levels should be managed as clinically appropriate. Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (triglycerides &gt;1000 mg/dL) may result in <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Discontinuation of ribavirin capsules/INTRON A therapy should be considered for patients with persistently elevated triglycerides (triglycerides &gt;1000 mg/dL) associated with symptoms of potential <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>: <a href="#i4i_section_ID_31E46B7B-6345-407F-8B87-4BF7CEDD9D90">Other</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_D4E0450D-F32A-45CD-B8E5-1D6448F173D3"></a><a name="section-17.2"></a><p></p>
<h2>Drug Interactions</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_07E4755E-1F2A-4321-B8BD-EDD81D6FC120"></a><a name="section-17.3"></a><p></p>
<h2>Nucleoside Analogs</h2>
<p class="First">Administration of nucleoside analogues has resulted in fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Coadministration of ribavirin and nucleoside analogues should be undertaken with caution and only if the potential benefit outweighs the potential risks.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_BFAF1B2B-E0F4-40B0-BA30-D6F6A4128D40"></a><a name="section-17.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Combination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> has been obtained immediately prior to initiation of therapy. Patients must perform a pregnancy test monthly during therapy and for 6 months posttherapy. Females of childbearing potential must be counseled about use of effective contraception (two reliable forms) prior to initiating therapy. Patients (male and female) must be advised of the teratogenic/embryocidal risks and must be instructed to practice effective contraception during combination ribavirin capsules/INTRON A therapy and for 6 months posttherapy. Patients (male and female) should be advised to notify the physician immediately in the event of a pregnancy. (See <span class="Bold"><a href="#i4i_contraindications_ID_8C649737-6D26-4CCD-930E-89571B019518">CONTRAINDICATIONS</a></span>).</p>
<p>If pregnancy does occur during treatment or during 6 months posttherapy, the patient must be advised of the significant teratogenic risk of ribavirin capsules therapy to the fetus. Patients, or partners of patients, should immediately report any pregnancy that occurs during treatment or within 6 months after treatment cessation to their physician. Physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214.</p>
<p>Patients receiving combination ribavirin capsules/INTRON A treatment should be directed in its appropriate use, informed of the benefits and risks associated with treatment, and referred to the Appendix of the Medication Guide on ribavirin capsules. There are no data evaluating whether ribavirin capsules/INTRON A therapy will prevent transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. Also, it is not known if treatment with ribavirin capsules/INTRON A therapy will cure <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C or prevent cirrhosis, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, or liver cancer that may be the result of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus.</p>
<p>If home use is prescribed, a puncture-resistant container for the disposal of used syringes and needles should be supplied to the patient. Patients should be thoroughly instructed in the importance of proper disposal and cautioned against any reuse of needles and syringes. The full container should be disposed of according to the directions provided by the physician. [see Appendix to the Medication Guide on ribavirin capsules.] To avoid possible transmission of disease, do not share your multidose pen with anyone; it is for you and you alone.</p>
<p>The most common adverse experiences occurring with combination ribavirin capsules/INTRON A therapy are “flu-like? symptoms, such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (see <span class="Bold"><a href="#i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331">ADVERSE REACTIONS</a></span>) and appear to decrease in severity as treatment continues. Some of these “flu-like? symptoms may be minimized by bedtime administration of INTRON A therapy. Antipyretics should be considered to prevent or partially alleviate the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Another common adverse experience associated with INTRON A therapy is thinning of the hair.</p>
<p>Patients should be advised that laboratory evaluations are required prior to starting therapy and periodically thereafter (see <span class="Bold"><a href="#i4i_lab_tests_ID_5C1470FB-A1EC-47D5-90A7-22B278E8069F">Laboratory Tests</a></span>). It is advised that patients be well hydrated, especially during the initial stages of treatment.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_ID_5C1470FB-A1EC-47D5-90A7-22B278E8069F"></a><a name="section-17.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The following laboratory tests are recommended for all patients on combination ribavirin capsules/INTRON A therapy, prior to beginning treatment and then periodically thereafter.</p>
<ul>
<li>Standard hematologic tests – including hemoglobin (pretreatment, week 2 and week 4 of therapy, and as clinically appropriate [see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>]), complete and differential white blood cell counts, and platelet count.</li>
<li>Blood chemistries – liver function tests and TSH.</li>
<li>Pregnancy – including monthly monitoring for females of child bearing potential.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_55072642-1D2C-4835-AFD4-E26BBB2C3A11"></a><a name="section-17.6"></a><p></p>
<h2>Carcinogenesis and Mutagenesis</h2>
<p class="First">Carcinogenicity studies with interferon alfa-2b, recombinant have not been performed because neutralizing activity appears in the serum after multiple dosing in all of the animal species tested.</p>
<p>Ribavirin did not cause an increase in any tumor type when administered for 6 months in the transgenic p53 deficient mouse model at doses up to 300 mg/kg (estimated human equivalent of 25 mg/kg based on body surface area adjustment for a 60 kg adult; approximately 1.9 times the maximum recommended human daily dose). Ribavirin was non-carcinogenic when administered for 2 years to rats at doses up to 40 mg/kg (estimated human equivalent of 5.71 mg/kg based on body surface area adjustment for a 60 kg adult). However, this dose was less than the maximum tolerated dose, and therefore the study was not adequate to fully characterize the carcinogenic potential of ribavirin.</p>
<p>Mutagenicity studies have demonstrated that interferon alfa-2b, recombinant is not mutagenic. Ribavirin demonstrated increased incidences of mutation and cell transformation in multiple genotoxicity assays. Ribavirin was active in the Balb/3T3 <span class="Italics">In Vitro</span> Cell Transformation Assay. Mutagenic activity was observed in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and at doses of 20 to 200 mg/kg (estimated human equivalent of 1.67 to 16.7 mg/kg, based on body surface area adjustment for a 60 kg adult; 0.1 to 1 times the maximum recommended human 24-hour dose of ribavirin) in a mouse micronucleus assay. A dominant lethal assay in rats was negative, indicating that if mutations occurred in rats they were not transmitted through male gametes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_28136083-B78F-4ADA-95EA-FCDA64AD29CE"></a><a name="section-17.7"></a><p></p>
<h2>Impairment of Fertility</h2>
<p class="First">No reproductive toxicology studies have been performed using interferon alfa-2b, recombinant in combination with ribavirin. However, evidence provided below for interferon alfa-2b, recombinant and ribavirin when administered alone indicate that both agents have adverse effects on reproduction. It should be assumed that the effects produced by either agent alone will also be caused by the combination of the two agents. Interferons may impair human fertility. In studies of interferon alfa-2b recombinant administration in nonhuman primates, menstrual cycle abnormalities have been observed. Decreases in serum estradiol and progesterone concentrations have been reported in females treated with human leukocyte interferon. In addition, ribavirin demonstrated significant embryocidal and/or teratogenic effects at doses well below the recommended human dose in all animal species in which adequate studies have been conducted.</p>
<p>Fertile females and partners of fertile females should not receive combination ribavirin capsules/INTRON A therapy unless the patient and his/her partner are using effective contraception (two reliable forms). Based on a multiple dose half-life (t<span class="Sub">1/2 </span>) of ribavirin of 12 days, effective contraception must be utilized for 6 months posttherapy (e.g., 15 half-lives of clearance for ribavirin).</p>
<p>Combination ribavirin capsules/INTRON A therapy should be used with caution in fertile males. In studies in mice to evaluate the time course and reversibility of ribavirin-induced testicular degeneration at doses of 15 to 150 mg/kg/day (estimated human equivalent of 1.25 to 12.5 mg/kg/day, based on body surface area adjustment for a 60 kg adult; 0.1 to 0.8 times the maximum human 24-hour dose of ribavirin) administered for 3 or 6 months, abnormalities in sperm occurred. Upon cessation of treatment, essentially total recovery from ribavirin-induced testicular toxicity was apparent within 1 or 2 spermatogenesis cycles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D31FD0D4-5481-4AD7-8B5A-15C8C50543E9"></a><a name="section-17.8"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First">Long-term studies in the mouse and rat (18 to 24 months; doses of 20 to 75 and 10 to 40 mg/kg/day, respectively [estimated human equivalent doses of 1.67 to 6.25 and 1.43 to 5.71 mg/kg/day, respectively, based on body surface area adjustment for a 60 kg adult; approximately 0.1 to 0.4 times the maximum human 24-hour dose of ribavirin]) have demonstrated a relationship between chronic ribavirin exposure and increased incidences of vascular lesions (microscopic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>) in mice. In rats, <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> occurred in controls, but the incidence was increased in ribavirin-treated rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F81A90B6-33E1-4161-B0D6-0DA219D7503E"></a><a name="section-17.9"></a><p></p>
<h2>Pregnancy Category X:</h2>
<p class="First">(See <span class="Bold"><a href="#i4i_contraindications_ID_8C649737-6D26-4CCD-930E-89571B019518">CONTRAINDICATIONS</a></span>.)</p>
<p>Interferon alfa-2b, recombinant has been shown to have abortifacient effects in <span class="Italics">Macaca mulatta </span>(rhesus monkeys) at 15 and 30 million IU/kg (estimated human equivalent of 5 and 10 million IU/kg, based on body surface area adjustment for a 60 kg adult). There are no adequate and well-controlled studies in pregnant females.</p>
<p>Ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton, and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with escalation of the drug dose. Survival of fetuses and offspring was reduced. In conventional embryotoxicity/<span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies in rats and rabbits, observed no effect dose levels were well below those for proposed clinical use (0.3 mg/kg/day for both the rat and rabbit; approximately 0.06 times the recommended human 24-hour dose of ribavirin). No maternal toxicity or effects on offspring were observed in a peri/postnatal toxicity study in rats dosed orally at up to 1 mg/kg/day (estimated human equivalent dose of 0.17 mg/kg based on body surface area adjustment for a 60 kg adult; approximately 0.01 times the maximum recommended human 24-hour dose of ribavirin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_2CCEE2F8-A163-46C1-973C-7E46E1C15E8C"></a><a name="section-17.10"></a><p></p>
<h2>Treatment and Posttreatment</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_809A54C5-7A3F-412F-95C4-02B9D3B3758B"></a><a name="section-17.11"></a><p></p>
<h2>Potential Risk to the Fetus</h2>
<p class="First">Ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. It is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. In a study in rats, it was concluded that dominant lethality was not induced by ribavirin at doses up to 200 mg/kg for 5 days (estimated human equivalent doses of 7.14 to 28.6 mg/kg, based on body surface area adjustment for a 60 kg adult; up to 1.7 times the maximum recommended human dose of ribavirin). However, because of the potential human teratogenic effects of ribavirin, male patients should be advised to take every precaution to avoid risk of pregnancy for their female partners.</p>
<p>Females of childbearing potential should not receive combination ribavirin capsules/INTRON A therapy unless they are using effective contraception (two reliable forms) during the therapy period. In addition, effective contraception should be utilized for 6 months posttherapy based on a multiple dose half-life (t<span class="Sub">1/2</span>) of ribavirin of 12 days.</p>
<p>Male patients and their female partners must practice effective contraception (two reliable forms) during treatment with combination ribavirin capsules/INTRON A therapy and for the 6-month posttherapy period (e.g., 15 half-lives for ribavirin clearance from the body).</p>
<p>If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment cessation, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at (800) 593-2214.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E204CE95-CBD6-4F57-9C35-4E2B42C97648"></a><a name="section-17.12"></a><p></p>
<h2>Ribavirin Pregnancy Registry</h2>
<p class="First">A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment and for six months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_2EEB6ED5-A02B-43AE-A679-CC7E25B023AB"></a><a name="section-17.13"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether ribavirin capsules and INTRON A are excreted in human milk. However, studies in mice have shown that mouse interferons are excreted into the milk. Because of the potential for serious adverse reactions from the drugs in nursing infants, a decision should be made whether to discontinue nursing or to discontinue combination ribavirin capsules/INTRON A therapy, taking into account the importance of the therapy to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_B5BEB2CB-1B26-4B70-B98E-D4CF1C979AFF"></a><a name="section-17.14"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span> or attempts occurred more frequently among pediatric patients compared to adult patients (2.4% versus 1%) during treatment and off therapy follow-up (see <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>). </span>As in adult patients, pediatric patients experienced other psychiatric adverse events (e.g., <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>). During a 48 week course of therapy there was a decrease in the rate of linear growth (mean percentile assignment decrease of 7%) and a decrease in the rate of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (mean percentile assignment decrease of 9%). A general reversal of these trends was noted during the 24 week post treatment period.</p>
<p>Injection site disorders, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> occurred more frequently in pediatric patients compared to adult patients. Conversely, pediatric patients experienced less <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, impaired concentration, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and pruritis compared to adult patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_2A77A7F4-B44E-4013-A782-B9BED0235634"></a><a name="section-17.15"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of combination therapy of ribavirin capsules taken together with INTRON A did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. In clinical trials, elderly subjects had a higher frequency of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (67%) than did younger patients (28%) (see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>).</p>
<p>In general, ribavirin capsules should be administered to elderly patients cautiously, starting at the lower end of the dosing range, reflecting the greater frequency of decreased renal, hepatic and/or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Ribavirin capsules are known to be substantially excreted by the kidney, and the risk of adverse reactions to ribavirin may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients often have decreased renal function, care should be taken in dose selection. Renal function should be monitored and dosage adjustments of ribavirin should be made accordingly (see <span class="Bold"><a href="#i4i_dosage_admin_ID_DFAFA8B6-5782-47DE-A5D9-F602EFF9A399">DOSAGE AND ADMINISTRATION</a>: Guidelines for Dose Modification</span>). Ribavirin capsules should not be used in elderly patients with creatinine clearance &lt;50 mL/min (see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>).</p>
<p>Ribavirin capsules taken together with INTRON A should be used very cautiously in elderly patients with a history of psychiatric disorders (see <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>).</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331"></a><a name="section-18"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The safety of combination ribavirin capsules/INTRON A therapy was evaluated in controlled trials of 1010 HCV-infected adults who were previously untreated with interferon therapy and were subsequently treated for 24 or 48 weeks with combination ribavirin capsules/INTRON A therapy and in 173 HCV-infected patients who had relapsed after interferon therapy and were subsequently treated for 24 weeks with combination ribavirin capsules/INTRON A therapy. (See <span class="Bold"><a href="#i4i_section_ID_52859A16-7321-44BE-AE65-0079A0119248">Description of Clinical Studies</a></span>.) Overall, 19% and 6% of previously untreated and relapse patients, respectively, discontinued therapy due to adverse events in the combination arms compared to 13% and 3% in the interferon arms.</p>
<p><span class="Bold">The primary toxicity of ribavirin is <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. Reductions in hemoglobin levels occurred within the first 1 to 2 weeks of therapy (see <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>). Cardiac and pulmonary events associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occurred in approximately 10% of patients treated with ribavirin capsules/INTRON A therapy. (See <a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a>.)</span></p>
<p>The most common psychiatric events occurring in US studies of previously untreated and relapse patients treated with ribavirin capsules/INTRON A therapy, respectively, were <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (39%, 26%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (34%, 23%), and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (27%, 25%). <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> (ideation, attempts, and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span>) occurred in 1% of patients. (See <span class="Bold"><a href="#i4i_warnings_ID_0232F072-F1C9-44B7-BD95-CF767FB8FC57">WARNINGS</a></span>.) In addition, the following spontaneous adverse events have been reported during the marketing surveillance of ribavirin capsules/INTRON A therapy: hearing disorder and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Very rarely, combination ribavirin capsules/INTRON A therapy may be associated with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>.</p>
<p>Selected treatment-emergent adverse events that occurred in the US studies with ≥5% incidence are provided in <span class="Bold">TABLE 4</span> by treatment group. In general, the selected treatment-emergent adverse events reported with lower incidence in the international studies as compared to the US studies with the exception of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<br><a name="ID_9C4F4E87-5C75-4086-9E3D-15A256DE8DE5"></a><table border="single" frame="box" width="623.000">
<caption><span>TABLE 4. Selected Treatment-Emergent Adverse Events: Previously Untreated and Relapse Patients</span></caption>
<col width="30.7%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd>Patients reporting one or more adverse events. A patient may have reported more than one adverse event within a body system/organ class category.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="6" valign="bottom"><span class="Bold">Percentage of Patients</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="4" valign="bottom"><span class="Bold">US Previously Untreated Study</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">US Relapse Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Patients Reporting</span></p>
<span class="Bold">Adverse Events<a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a></span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=76)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Application Site Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span></td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">12</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom"> 8</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span></td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 3</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Body as a Whole –</span></p>
<span class="Bold">General Disorders</span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="bottom">63</td>
<td align="center" valign="bottom">63</td>
<td align="center" valign="bottom">66</td>
<td align="center" valign="bottom">67</td>
<td align="center" valign="bottom">66</td>
<td align="center" valign="bottom">68</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="bottom">68</td>
<td align="center" valign="bottom">62</td>
<td align="center" valign="bottom">70</td>
<td align="center" valign="bottom">72</td>
<td align="center" valign="bottom">60</td>
<td align="center" valign="bottom">53</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td align="center" valign="bottom">40</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">42</td>
<td align="center" valign="bottom">39</td>
<td align="center" valign="bottom">43</td>
<td align="center" valign="bottom">37</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center" valign="bottom">37</td>
<td align="center" valign="bottom">35</td>
<td align="center" valign="bottom">41</td>
<td align="center" valign="bottom">40</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">36</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">18</td>
<td align="center" valign="bottom">18</td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom">13</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom"> 7</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Central &amp; Peripheral</span></p>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">15</td>
<td align="center" valign="bottom">23</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom">26</td>
<td align="center" valign="bottom">21</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Gastrointestinal System Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="bottom">38</td>
<td align="center" valign="bottom">35</td>
<td align="center" valign="bottom">46</td>
<td align="center" valign="bottom">33</td>
<td align="center" valign="bottom">47</td>
<td align="center" valign="bottom">33</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom">14</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom"> 9</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="center" valign="bottom">11</td>
<td class="Botrule" align="center" valign="bottom">10</td>
<td class="Botrule" align="center" valign="bottom"> 9</td>
<td class="Botrule" align="center" valign="bottom">13</td>
<td class="Botrule" align="center" valign="bottom">12</td>
<td class="Botrule" align="center" valign="bottom"> 8</td>
</tr>
</tbody>
</table>
<br><a name="ID_F37D657A-8592-4BD5-80EC-12DF2C01BA29"></a><table border="single" frame="box" width="623.000">
<caption><span>TABLE 4. Selected Treatment-Emergent Adverse Events: Previously Untreated and Relapse Patients (continued)</span></caption>
<col width="30.7%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<col width="11.6%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-28" href="#footnote-reference-28">*</a></dt>
<dd>Patients reporting one or more adverse events. A patient may have reported more than one adverse event within a body system/organ class category.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="6" valign="bottom"><span class="Bold">Percentage of Patients</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="4" valign="bottom"><span class="Bold">US Previously Untreated Study</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">US Relapse Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Patients Reporting</span></p>
<span class="Bold">Adverse Events</span><a name="footnote-reference-28" href="#footnote-28" class="Sup">*</a>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Ribavirin</span></p>
<p><span class="Bold">capsules</span></p>
<span class="Bold">(N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<p><span class="Bold">plus</span></p>
<p><span class="Bold">Placebo</span></p>
<span class="Bold">(N=76)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Musculoskeletal System Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="bottom">61</td>
<td align="center" valign="bottom">57</td>
<td align="center" valign="bottom">64</td>
<td align="center" valign="bottom">63</td>
<td align="center" valign="bottom">61</td>
<td align="center" valign="bottom">58</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" valign="bottom">30</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">33</td>
<td align="center" valign="bottom">36</td>
<td align="center" valign="bottom">29</td>
<td align="center" valign="bottom">29</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom">26</td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">22</td>
<td align="center" valign="bottom">28</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="bottom">39</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">39</td>
<td align="center" valign="bottom">30</td>
<td align="center" valign="bottom">26</td>
<td align="center" valign="bottom">25</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td align="center" valign="bottom">23</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">20</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">25</td>
<td align="center" valign="bottom">36</td>
<td align="center" valign="bottom">37</td>
<td align="center" valign="bottom">23</td>
<td align="center" valign="bottom">14</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional lability</span></td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom">11</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom">12</td>
<td align="center" valign="bottom"> 8</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Concentration impaired</span></td>
<td align="center" valign="bottom">11</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">18</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">17</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom">10</td>
<td align="center" valign="bottom">14</td>
<td align="center" valign="bottom">12</td>
<td align="center" valign="bottom"> 7</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Skin and Appendages Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom">27</td>
<td align="center" valign="bottom">26</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="bottom">20</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">28</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 5</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom">19</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom">13</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">Special Senses, Other Disorders</span></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td class="Botrule" align="center" valign="bottom"> 7</td>
<td class="Botrule" align="center" valign="bottom"> 4</td>
<td class="Botrule" align="center" valign="bottom"> 8</td>
<td class="Botrule" align="center" valign="bottom"> 4</td>
<td class="Botrule" align="center" valign="bottom"> 6</td>
<td class="Botrule" align="center" valign="bottom"> 5</td>
</tr>
</tbody>
</table>
<br><div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_86853106-EB1F-4524-B257-4E08DB5416CD"></a><a name="section-18.1"></a><p></p>
<h2>Laboratory Values</h2>
<p class="First">Changes in selected hematologic values (hemoglobin, white blood cells, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, and platelets) during combination ribavirin capsules/INTRON A treatment are described below (see <span class="Bold">TABLE 5</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_FEADF610-6F81-4C3E-AC9F-7458F2863351"></a><a name="section-18.2"></a><p></p>
<h2>Hemoglobin</h2>
<p class="First">Hemoglobin decreases among patients on combination therapy began at Week 1, with stabilization by Week 4. In previously untreated patients treated for 48 weeks the mean maximum decrease from baseline was 3.1 g/dL in the US study and 2.9 g/dL in the International study. In relapse patients the mean maximum decrease from baseline was 2.8 g/dL in the US study and 2.6 g/dL in the International study. Hemoglobin values returned to pretreatment levels within 4 to 8 weeks of cessation of therapy in most patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_DE2000B4-BDC4-4405-8058-57B000FDC674"></a><a name="section-18.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></h2>
<p class="First">There were decreases in neutrophil counts in both the combination ribavirin capsules/INTRON A and INTRON A plus placebo dose groups. In previously untreated patients treated for 48 weeks the mean maximum decrease in neutrophil count in the US study was 1.3x 10<span class="Sup">9</span>/L and in the International study was 1.5 x 10<span class="Sup">9</span>/L. In relapse patients the mean maximum decrease in neutrophil count in the US study was 1.3 x 10<span class="Sup">9</span>/L and in the International study was 1.6 x 10<span class="Sup">9</span>/L. Neutrophil counts returned to pretreatment levels within 4 weeks of cessation of therapy in most patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_C745AA07-D143-420C-BAF5-D68DD04D4A80"></a><a name="section-18.4"></a><p></p>
<h2>Platelets</h2>
<p class="First">In both previously untreated and relapse patients mean platelet counts generally remained in the normal range in all treatment groups, however, mean platelet counts were 10% to 15% lower in the INTRON A plus placebo group than the ribavirin capsules/INTRON A group. Mean platelet counts returned to baseline levels within 4 weeks after treatment discontinuation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8D27F0BF-EDE4-4AC3-AD81-2E12EB0937DC"></a><a name="section-18.5"></a><p></p>
<h2>Thyroid Function</h2>
<p class="First">Of patients who entered the previously untreated (24 and 48 week treatment) and relapse (24 week treatment) studies without thyroid abnormalities, approximately 3% to 6% and 1% to 2%, respectively, developed thyroid abnormalities requiring clinical intervention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_FFEE8181-1584-4A0C-B7F7-0A1688C97B4E"></a><a name="section-18.6"></a><p></p>
<h2>Bilirubin and Uric Acid</h2>
<p class="First">Increases in both bilirubin and uric acid, associated with <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, were noted in clinical trials. Most were moderate biochemical changes and were reversed within 4 weeks after treatment discontinuation. This observation occurs most frequently in patients with a previous diagnosis of Gilbert’s syndrome. This has not been associated with hepatic dysfunction or clinical morbidity.</p>
<br><a name="ID_D5B0CAAD-7F85-4EF0-BC6D-32E7F2EA61BE"></a><table border="single" frame="box" width="934.000">
<caption><span>TABLE 5. Selected Hematologic Values During Treatment with Ribavirin Capsules plus INTRON A: Previously Untreated and Relapse Patients</span></caption>
<col width="14.0%">
<col width="16.0%">
<col width="13.0%">
<col width="15.8%">
<col width="13.0%">
<col width="15.8%">
<col width="12.4%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" colspan="6" valign="bottom"><span class="Bold">Percentage of Patients</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="4" valign="bottom"><span class="Bold">US Previously Untreated Study</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">US Relapse Study</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">48 weeks of treatment</span></td>
<td align="center" colspan="2" valign="bottom"><span class="Bold">24 weeks of treatment</span></td>
</tr>
<tr>
<td align="left" valign="bottom"></td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Ribavirin (N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Placebo (N=231)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Ribavirin (N=228)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Placebo (N=225)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Ribavirin (N=77)</span>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">INTRON A</span></p>
<span class="Bold">plus Placebo (N=76)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">Hemoglobin (g/dL)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">9.5-10.9</td>
<td align="center" valign="bottom"> 24</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom"> 32</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 3</td>
</tr>
<tr>
<td align="left" valign="bottom">8.0-9.4</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">6.5-7.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;6.5</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">Leukocytes (x10<span class="Sup">9</span>/L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">2.0-2.9</td>
<td align="center" valign="bottom"> 40</td>
<td align="center" valign="bottom"> 20</td>
<td align="center" valign="bottom"> 38</td>
<td align="center" valign="bottom"> 23</td>
<td align="center" valign="bottom">45</td>
<td align="center" valign="bottom">26</td>
</tr>
<tr>
<td align="left" valign="bottom">1.5-1.9</td>
<td align="center" valign="bottom"> 4</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 3</td>
</tr>
<tr>
<td align="left" valign="bottom">1.0-1.4</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;1.0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (x10<span class="Sup">9</span>/L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">1.0-1.49</td>
<td align="center" valign="bottom"> 30</td>
<td align="center" valign="bottom"> 32</td>
<td align="center" valign="bottom"> 31</td>
<td align="center" valign="bottom"> 44</td>
<td align="center" valign="bottom">42</td>
<td align="center" valign="bottom">34</td>
</tr>
<tr>
<td align="left" valign="bottom">0.75-0.99</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 15</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom">16</td>
<td align="center" valign="bottom">18</td>
</tr>
<tr>
<td align="left" valign="bottom">0.5-0.74</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 7</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 4</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;0.5</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 8</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 5</td>
<td align="center" valign="bottom"> 8</td>
</tr>
<tr>
<td align="left" valign="bottom">Platelets (x10<span class="Sup">9</span>/L)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">70-99</td>
<td align="center" valign="bottom"> 9</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 11</td>
<td align="center" valign="bottom"> 14</td>
<td align="center" valign="bottom"> 6</td>
<td align="center" valign="bottom">12</td>
</tr>
<tr>
<td align="left" valign="bottom">50-69</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 3</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 3</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 5</td>
</tr>
<tr>
<td align="left" valign="bottom">30-49</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">&lt;30</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 1</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">Total Bilirubin (mg/dL)</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="bottom">1.5-3.0</td>
<td align="center" valign="bottom"> 27</td>
<td align="center" valign="bottom"> 13</td>
<td align="center" valign="bottom"> 32</td>
<td align="center" valign="bottom"> 13</td>
<td align="center" valign="bottom">21</td>
<td align="center" valign="bottom"> 7</td>
</tr>
<tr>
<td align="left" valign="bottom">3.1-6.0</td>
<td align="center" valign="bottom">0.9</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 2</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 3</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td align="left" valign="bottom">6.1-12.0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom">0.4</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
<td align="center" valign="bottom"> 0</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">&gt;12.0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
<td class="Botrule" align="center" valign="bottom"> 0</td>
</tr>
</tbody>
</table>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_E41333A4-68C3-44A6-8A0A-E97E483D7FFA"></a><a name="section-19"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is limited experience with overdosage. Acute ingestion of up to 20 grams of ribavirin capsules, INTRON A ingestion of up to 120 million units, and subcutaneous doses of INTRON A up to 10 times the recommended doses have been reported. Primary effects that have been observed are increased incidence and severity of the adverse events related to the therapeutic use of INTRON A and ribavirin capsules. However, hepatic enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported with administration of single subcutaneous doses of INTRON A that exceed dosing recommendations.</p>
<p>There is no specific antidote for INTRON A or ribavirin capsules, and hemodialysis and peritoneal dialysis are not effective for treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of either agent.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_DFAFA8B6-5782-47DE-A5D9-F602EFF9A399"></a><a name="section-20"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">INTRON A Injection should be administered subcutaneously and ribavirin capsules should be administered orally. Ribavirin capsules may be administered without regard to food, but should be administered in a consistent manner. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_8BB60E0F-79C2-420E-8BAE-3222275F292C">CLINICAL PHARMACOLOGY</a></span>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_DD762AA3-7E5B-453A-B624-914EF9B2D62D"></a><a name="section-20.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The recommended dose of ribavirin capsules in patients 18 years of age and older depends on the patient’s body weight. The recommended doses of ribavirin capsules and INTRON A for adults are given in <span class="Bold">TABLE 6</span>.</p>
<p>The recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. The duration of treatment should be individualized to the patient depending on baseline disease characteristics, response to therapy, and tolerability of the regimen (see <span class="Bold"><a href="#i4i_section_ID_52859A16-7321-44BE-AE65-0079A0119248">Description of Clinical Studies</a></span> and <span class="Bold"><a href="#i4i_adverse_effects_ID_9D55DD74-6AF6-4C59-9E58-952C00361331">ADVERSE REACTIONS</a></span>). After 24 weeks of treatment virologic response should be assessed. Treatment discontinuation should be considered in any patient who has not achieved an HCV-RNA below the limit of detection of the assay by 24 weeks. There are no safety and efficacy data on treatment for longer than 48 weeks in the previously untreated patient population.</p>
<p>In patients who relapse following interferon therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in the relapse patient population.</p>
<a name="ID_5A88DC95-92A2-4BEE-A690-12096E1D689F"></a><table border="single" frame="box" width="441.000">
<caption><span>TABLE 6. Recommended Adult Dosing</span></caption>
<col width="34.0%">
<col width="35.1%">
<col width="30.8%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold">Body Weight</span></td>
<td class="Toprule" align="left" valign="bottom"><span class="Bold">Ribavirin Capsules</span></td>
<td class="Toprule" align="left" valign="bottom"><span class="Bold">INTRON A Injection</span></td>
</tr>
<tr>
<td align="left" valign="bottom"><p class="First">≤75 kg</p></td>
<td align="left" valign="bottom">
<p class="First">2 x 200 mg capsules AM,</p>
<p>3 x 200 mg capsules PM</p>
daily p.o.</td>
<td align="left" valign="bottom">
<p class="First">3 million</p>
<p>IU 3 times weekly s.c.</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><p class="First">&gt;75 kg</p></td>
<td class="Botrule" align="left" valign="bottom">
<p class="First">3 x 200 mg capsules AM,</p>
<p>3 x 200 mg capsules PM</p>
daily p.o.</td>
<td class="Botrule" align="left" valign="bottom">
<p class="First">3 million</p>
<p>IU 3 times weekly s.c.</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Under no circumstances should ribavirin capsules be opened, crushed or broken (see CONTRAINDICATIONS and WARNINGS).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_EAEBD49D-3DF3-4E70-96D4-B98714061D3D"></a><a name="section-20.2"></a><p></p>
<h2>Dose Modifications</h2>
<p class="First">(See <span class="Bold">TABLE 7</span>.)</p>
<p>In clinical trials, approximately 26% of patients required modification of their dose of ribavirin capsules, INTRON A Injection, or both agents. If severe adverse reactions or laboratory abnormalities develop during combination ribavirin capsules/INTRON A therapy the dose should be modified, or discontinued if appropriate, until the adverse reactions abate. If intolerance persists after dose adjustment, ribavirin capsules/INTRON A therapy should be discontinued.</p>
<p>Ribavirin capsules/INTRON A therapy should be administered with caution to patients with preexisting cardiac disease. Patients should be assessed before commencement of therapy and should be appropriately monitored during therapy. If there is any deterioration of cardiovascular status, therapy should be stopped. (See <span class="Bold">WARNINGS</span>.)</p>
<p>For patients with a history of stable cardiovascular disease, a permanent dose reduction is required if the hemoglobin decreases by ≥2 g/dL during any 4-week period. In addition, for these cardiac history patients, if the hemoglobin remains &lt;12 g/dL after 4 weeks on a reduced dose, the patient should discontinue combination ribavirin capsules/INTRON A therapy.</p>
<p>It is recommended that a patient whose hemoglobin level <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 10 g/dL have his/her ribavirin capsules dose reduced to 600 mg daily (1 x 200 mg capsule AM, 2 x 200 mg capsules PM). A patient whose hemoglobin level <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 8.5 g/dL should be permanently discontinued from ribavirin capsules/INTRON A therapy. (See <span class="Bold">WARNINGS</span>.)</p>
<p>It is recommended that a patient who experiences moderate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (persistent low mood, loss of interest, poor self image, and/or hopelessness) have his/her INTRON A dose temporarily reduced and/or be considered for medical therapy. A patient experiencing severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>/attempt should be discontinued from ribavirin capsules/INTRON A therapy and followed closely with appropriate medical management. (See <span class="Bold">WARNINGS</span>.) </p>
<br><a name="ID_0918F1CE-70FD-4C1F-9030-A8335D3DF91F"></a><table border="single" frame="box" width="441.000">
<caption><span>TABLE 7. Guidelines for Dose Modifications</span></caption>
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-29" href="#footnote-reference-29">*</a></dt>
<dd>Study medication to be dose reduced is shown in parenthesis.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Dose Reduction</span><a name="footnote-reference-29" href="#footnote-29" class="Sup">*</a></p>
<p><span class="Bold">Ribavirin capsules –</span></p>
<p><span class="Bold">Adults 600 mg daily</span></p>
<p><span class="Bold">INTRON A <span class="Bold">–</span> Adults</span></p>
<span class="Bold">1.5 million IU TIW</span>
</td>
<td class="Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Permanent</span></p>
<p><span class="Bold">Discontinuation</span></p>
<p><span class="Bold">of Treatment</span></p>
<p><span class="Bold">Ribavirin capsules</span></p>
<span class="Bold">and INTRON A</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><p class="First">Hemoglobin</p></td>
<td align="center" valign="bottom">
<p class="First">&lt;10 g/dL</p>
(Ribavirin capsules)</td>
<td align="center" valign="bottom"><p class="First">&lt;8.5 g/dL</p></td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First"><span class="Bold">Cardiac History</span></p>
<p><span class="Bold">Patients Only</span></p>
</td>
<td align="center" valign="bottom">
<p class="First"><span class="Bold">≥2 g/dL decrease</span></p>
<p><span class="Bold">during any 4-week</span></p>
<p><span class="Bold">period during treatment</span></p>
<p><span class="Bold">(Ribavirin capsules/</span></p>
<span class="Bold">INTRON A)</span>
</td>
<td align="center" valign="bottom">
<p class="First">&lt;<span class="Bold">12 g/dL after</span></p>
<p><span class="Bold">4 weeks of dose</span></p>
<p><span class="Bold">reduction</span></p>
</td>
</tr>
<tr>
<td align="left" valign="bottom">White blood count</td>
<td align="center" valign="bottom">&lt;1.5 x 10<span class="Sup">9</span>/L (INTRON A)</td>
<td align="center" valign="bottom">&lt;1.0 X 10<span class="Sup">9</span>/L</td>
</tr>
<tr>
<td align="left" valign="bottom">Neutrophil count</td>
<td align="center" valign="bottom">&lt;0.75 x 10<span class="Sup">9</span>/L (INTRON A)</td>
<td align="center" valign="bottom">&lt;0.5 X 10<span class="Sup">9</span>/L</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom"><p class="First">Platelet count</p></td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">Adults: &lt;50 x 10<span class="Sup">9</span>/L</p>
(INTRON A)</td>
<td class="Botrule" align="center" valign="bottom"><p class="First">Adults: &lt;25 x 10<span class="Sup">9</span>/L</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8F91FEAE-4E22-43CD-8683-7DE35932E3AB"></a><a name="section-20.3"></a><p></p>
<h2>Administration of INTRON A Injection</h2>
<p class="First">At the discretion of the physician, the patient may self-administer the INTRON A. [See illustrated Appendix to Medication Guide on ribavirin capsules for instructions.]</p>
<p>The Intron A Injection is supplied as a clear and colorless solution. The appropriate INTRON A dose should be withdrawn from the vial or set on the multidose pen and injected subcutaneously. The INTRON A Injection supplied with the B-D Safety Lok™ syringes contain a plastic sleeve to be pulled over the needle after use. The syringe locks with an audible click when the green stripe on the safety sleeve covers the red stripe on the needle. After administration of INTRON A Injection, it is essential to follow the procedure for proper disposal of syringes and needles. [See Appendix to Medication Guide on ribavirin capsules for detailed instructions.] </p>
<a name="ID_D17CD43B-BF32-461F-9B26-DB230811CEF0"></a><table border="single" frame="box" width="442.000">
<col width="41.9%">
<col width="25.8%">
<col width="32.4%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-30" href="#footnote-reference-30">*</a></dt>
<dd>This is a multidose vial which contains a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL in order to provide the delivery of six 0.5-mL doses, each containing 3 million IU of interferon alfa-2b, recombinant (for a label strength of 18 million IU).</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">†</a></dt>
<dd>This is a multidose pen which contains a total of 22.5 million IU of interferon alfa-2b, recombinant per 1.5 mL in order to provide the delivery of six 0.2-mL doses, each containing 3 million IU of interferon alfa-2b, recombinant (for a label strength of 18 million IU).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold">Vial/Pen Label Strength</span></td>
<td class="Toprule" align="center" valign="bottom"><span class="Bold">Fill Volume</span></td>
<td class="Toprule" align="center" valign="bottom"><span class="Bold">Concentration</span></td>
</tr>
<tr>
<td align="left" valign="bottom">3 million IU vial</td>
<td align="center" valign="bottom">0.5 mL</td>
<td align="center" valign="bottom">3 million IU/0.5 mL</td>
</tr>
<tr>
<td align="left" valign="bottom">18 million IU multidose vial<a name="footnote-reference-30" href="#footnote-30" class="Sup">*</a>
</td>
<td align="center" valign="bottom">3.8 mL</td>
<td align="center" valign="bottom">3 million IU/0.5 mL</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">18 million IU multidose pen<a name="footnote-reference-31" href="#footnote-31" class="Sup">†</a>
</td>
<td class="Botrule" align="center" valign="bottom">1.5 mL</td>
<td class="Botrule" align="center" valign="bottom">3 million IU/0.2 mL</td>
</tr>
</tbody>
</table>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. INTRON A Injection may be administered using either sterilized glass or plastic disposable syringes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F0E62DF0-5D73-4E0C-8B86-E29D659E24C1"></a><a name="section-20.4"></a><p></p>
<h2>Stability</h2>
<p class="First">INTRON A Injection provided in vials is stable at 35°C (95°F) for up to 7 days and at 30°C (86°F) for up to 14 days. INTRON A Injection provided in a multidose pen is stable at 30°C (86°F) for up to 2 days. The solution is clear and colorless.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_A3FB03A0-0EAB-4669-B032-70B1B692F954"></a><a name="section-21"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ribavirin capsules, 200 mg are white, opaque, hard gelatin capsules imprinted (in blue) RIBAVIRIN over 200 mg on cap and GG 608 on body.</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0781-1</td>
<td align="center">200 mg</td>
<td align="center">30 Capsules in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">WHITE</td>
<td align="center">0781-2043</td>
</tr></tbody>
</table>
<p>Dispense in a tight container as defined in the USP.</p>
<p>Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</p>
<p>INTRON A Injection is a clear, colorless solution packaged in single dose and multidose vials, and a multidose pen.</p>
<p>INTRON A Injection and the INTRON A Multidose Pen should be stored refrigerated between 2° and 8°C (36° and 46°F).</p>
<p>INTRON® A is a registered trademark of Schering Corporation.</p>
<p>Mylanta® is a registered trademark of Johnson &amp; Johnson-Merck Consumer Pharmaceuticals Co.</p>
<p>REBETOL® is a registered trademark of Schering Corporation.</p>
<p>REBETRON® is a registered trademark of Schering Corporation.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_ID_02BC8709-869C-4575-997D-122406099D74"></a><a name="section-22"></a><p></p>
<h1><span class="Bold">MEDICATION GUIDE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B7B8A3D6-5999-443E-B18E-3745F2592B03"></a><a name="section-22.1"></a><p></p>
<h2>Ribavirin Capsules 200 mg</h2>
<p class="First">Read this medication guide carefully before you begin taking ribavirin capsules, and each time you refill your prescription in case new information has been included. This summary does not tell you everything about ribavirin capsules. Your health care provider is the best source of information about this medicine. After reading this medication guide, talk with your health care provider if you have any questions about ribavirin.</p>
<p><span class="Underline"><span class="Bold">What is the most important information I should know about therapy with ribavirin capsules?</span></span></p>
<ul><li>
<span class="Bold">Ribavirin capsules may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of an unborn child. Therefore, if you are pregnant or your sexual partner is pregnant, do not take ribavirin.</span> If you could become pregnant, you must not become pregnant during therapy and for 6 months after you have stopped therapy. During this time you must use 2 forms of birth control, and you must have pregnancy tests that show that you are not pregnant.<br>Female sexual partners of male patients being treated with ribavirin must not become pregnant during treatment and for 6 months after treatment has stopped. Therefore, you must use 2 forms of birth control during this time.<br>If you or a female sexual partner becomes pregnant, you should tell your health care provider. There is a Ribavirin Pregnancy Registry that collects information about pregnancy outcomes in female patients and female partners of male patients exposed to ribavirin. You or your health care provider are encouraged to contact the Ribavirin Pregnancy Registry at 1-800-593-2214.<br>Be assured that any information you tell the Registry will be kept confidential. (See “<span class="Underline"><span class="Bold">What should I avoid while taking ribavirin capsules??</span></span>) </li></ul>
<ul>
<li>
<span class="Bold">Ribavirin capsules can cause a dangerous drop in your red blood cell count. </span>Ribavirin capsules can cause <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, which is a decrease in the number of red blood cells. This can be dangerous, especially if you have heart or breathing problems. Tell your health care provider before taking ribavirin if you have ever had any of these problems. Your health care provider should check your red blood cell count before you start therapy and often during the first 4 weeks of therapy. Your red blood cell count may be checked more often if you have any heart or breathing problems.</li>
<li>
<span class="Bold">Do not take ribavirin capsules alone to treat <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span> Ribavirin capsules should be used in combination with interferon alfa-2b (INTRON®<span class="Sup">1</span> A) for treating <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults.</li>
</ul>
<p>Please read the Appendix to this Medication Guide. It has additional important information about combination therapy not covered in this guide.</p>
<p><span class="Underline"><span class="Bold">What is ribavirin?</span></span></p>
<p>Ribavirin is an antiviral drug. It is used in combination with interferon alfa-2b to treat some patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. It is not known how ribavirin and interferon alfa-2b work together to fight <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<span class="Underline">See the Appendix to this Medication Guide.</span>)</p>
<p>It is not known if treatment with ribavirin and interferon alfa-2b will cure <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or prevent cirrhosis, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, or liver cancer that can be caused by <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. It is not known if treatment with ribavirin and interferon alfa-2b will prevent an infected person from infecting another person with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus.</p>
<p><span class="Underline"><span class="Bold">Who should not take ribavirin capsules?</span></span></p>
<p><span class="Bold">Do not use these medicines if:</span></p>
<ul>
<li>You are a female and you are pregnant or plan to become pregnant at any time during your treatment with ribavirin or during the 6 months after your treatment has ended.</li>
<li>You are a male patient with a female sexual partner who is pregnant or plans to become pregnant at any time while you are being treated with ribavirin or during the 6 months after your treatment has ended. (See “<span class="Underline"><span class="Bold">What is the most important information I should know about therapy with ribavirin capsules?? </span></span>and “<span class="Underline"><span class="Bold">What should I avoid while taking ribavirin capsules??</span></span>)</li>
<li>You are breast-feeding. Ribavirin may pass through your milk and harm your baby. Talk with your provider about whether you should stop breast-feeding.</li>
<li>You are allergic to any of the ingredients in ribavirin capsules. See the ingredients listed at the end of this Medication Guide on ribavirin capsules.</li>
</ul>
<p><span class="Bold">Tell your health care provider before starting treatment with ribavirin capsules in combination with interferon alfa-2b, if you have any of the following medical conditions: </span></p>
<ul>
<li>
<span class="Bold">mental health problems, such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</span> Ribavirin/Interferon alfa-2b therapy may make them worse. Tell your health care provider if you are being treated or had treatment in the past for any mental problems, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, or a feeling of loss of contact with reality, such as hearing voices or seeing things that are not there (<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>). Tell your health care provider if you take any medicines for these problems.</li>
<li>
<span class="Bold">high blood pressure, heart problems, or have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span> Ribavirin capsules may worsen heart problems. Patients who have had certain heart problems should not take ribavirin capsules.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span></span>, including <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (low red blood cell count), <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> (Mediterranean <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), and sickle-cell <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Ribavirin capsules can reduce the number of red blood cells you have. This may make you feel dizzy or weak and could worsen any heart problems you might have.</li>
<li>
<span class="Bold">kidney problems</span>. If your kidneys do not work properly, you may experience worse side effects from ribavirin therapy and require a lower dose.</li>
<li>
<span class="Bold">liver problems</span> (other than <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>).</li>
<li>
<span class="Bold">organ transplant</span>, and are taking medicine that keeps your body from rejecting your transplant (suppresses your immune system).</li>
<li>
<span class="Bold">thyroid disease</span>. Ribavirin/Interferon alfa-2b therapy may make your thyroid disease worse or harder to treat. Ribavirin/Interferon alfa-2b therapy may be stopped if you develop thyroid problems that cannot be controlled by medication.</li>
<li>
<span class="Bold">lung problems.</span> Ribavirin/Interferon alfa-2b therapy can cause breathing problems or worsen breathing problems you already have.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> or drug abuse or addiction</span></li>
<li><span class="Bold">cancer</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus and/or human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus</span>, the virus that causes AIDS.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span> Ribavirin/Interferon alfa-2b therapy may make your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> worse or harder to treat.</li>
<li><span class="Bold">past interferon treatment for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that did not work for you.</span></li>
</ul>
<p><span class="Bold">For more information see the Appendix to this Medication Guide.</span></p>
<p><span class="Underline"><span class="Bold">How should I take ribavirin capsules?</span></span></p>
<p>Your health care provider has determined the correct dose of ribavirin capsules based on your weight. Your health care provider may lower your dose of ribavirin if you have side effects.</p>
<ul>
<li>It is important to follow your dosing schedule and your health care provider’s instructions on how to take your medicines.</li>
<li>If you take ribavirin capsules with INTRON A, you can take it with or without food. However, you should <span class="Bold">take it the same way every day.</span>
</li>
<li>Take the medicine for as long as prescribed and do not take more than the recommended dose.</li>
<li>If you miss a dose of ribavirin capsules, take the missed dose as soon as possible during the same day. If an entire day has gone by, check with your health care provider about what to do. Do not double the next dose.</li>
<li>Tell your health care provider if you are taking or planning to take other prescription or non-prescription medicines, including vitamin and mineral supplements, and herbal medicines.</li>
<li>Tell your provider before taking ribavirin capsules if you have ever had any heart or breathing problems. Your provider should check your red blood cell count before starting therapy and often during the first 4 weeks of therapy. Your red blood cell count may be checked more frequently if you have had heart or breathing problems.</li>
<li>Females taking ribavirin capsules or female sexual partners of male patients taking ribavirin capsules must have a pregnancy test before treatment begins, every month during treatment, and for 6 months after treatment ends to make sure there is no pregnancy.</li>
</ul>
<p><span class="Underline"><span class="Bold">What should I avoid while taking ribavirin capsules?</span></span></p>
<p>Avoid the following during ribavirin capsule treatment:</p>
<ul>
<li>
<span class="Bold">Pregnancy:</span> If you or your sexual partner becomes pregnant during treatment with ribavirin capsules or in the 6 months after treatment ends, tell your health care provider right away. (See “<span class="Underline"><span class="Bold">What is the most important information I should know about therapy with ribavirin capsules??</span></span> at the beginning of this Medication Guide.)<br>Talk with your health care provider about how to avoid pregnancy. If you or your sexual partner becomes pregnant while on ribavirin or during the 6 months after your treatment ends, you must report the pregnancy to your health care provider right away. Your <span class="Italics">health care provider</span> should call the Ribavirin Pregnancy Registry at 1-800-593-2214. Your health care provider will be asked to give follow-up information about the pregnancy. Any information about your pregnancy that is reported about you will be confidential.</li>
<li>
<span class="Bold">Breastfeeding.</span> The medicine may pass through your milk and harm the baby.</li>
<li>
<span class="Bold">Drinking alcohol,</span> including beer, wine, and liquor. This may make your liver disease worse.</li>
<li>
<span class="Bold">Taking other medicines.</span> Take only medicines prescribed or approved by your health care provider. These include prescription and non-prescription medicines and herbal supplements.</li>
</ul>
<p><span class="Underline"><span class="Bold">What are the most common side effects of ribavirin capsules?</span></span></p>
<p><span class="Bold">The most serious possible side effects of ribavirin capsules are:</span></p>
<ul>
<li>
<span class="Bold">Harm to unborn children</span>. Ribavirin capsules may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of an unborn child. (For more details, see “<span class="Underline"><span class="Bold">What is the most important information I should know about therapy with ribavirin capsules??</span></span>)</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span>. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is a reduction in the number of red blood cells you have, which can be dangerous, especially if you have heart or breathing problems. Tell your health care provider right away if you feel tired, have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>. These may be signs of low red blood cell counts.</li>
</ul>
<p><span class="Bold">Tell your provider right away if you have any of the following symptoms. They may be signs of a serious side effect:</span></p>
<ul>
<li><span class="Bold">trouble breathing</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></span></li>
<li><span class="Bold">severe stomach or lower <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (bowel movements). These may appear black and tarry.</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></span></li>
<li><span class="Bold">other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
</ul>
<p><span class="Bold">The most common side effects of ribavirin capsules are:</span></p>
<ul>
<li><span class="Bold">feeling tired</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and appetite loss</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></span></li>
</ul>
<p>This summary does not include all possible side effects of ribavirin therapy Talk to your health care provider, if you do not feel well while taking ribavirin capsules. Your health care provider can give you more information about managing your side effects.</p>
<p><span class="Underline"><span class="Bold">What should I know about the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>?</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is a disease caused by a virus that infects the liver. This liver <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> becomes a continuing (chronic) condition in most patients. Patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may develop cirrhosis, liver cancer, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. The virus is spread from one person to another by contact with the infected person’s blood. You should talk to your health care provider about ways to prevent you from infecting others.</p>
<p><span class="Underline"><span class="Bold">How do I store my ribavirin capsules?</span></span></p>
<p>Store ribavirin capsules at 25°C (77°F) ; excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">General advice about prescription medicines</span></p>
<p>Do not use ribavirin capsules for conditions for which they were not prescribed. If you have any concern about ribavirin capsules, ask your health care provider. Your health care provider or pharmacist can give you information about ribavirin capsules that was written for health care professionals. Do not give this medicine to other people, even if they have the same condition you have.</p>
<p><span class="Bold">Ingredients:</span> Ribavirin capsules contain ribavirin and the inactive ingredients croscarmellose sodium, hypromellose, magnesium stearate, mannitol, and povidone. The capsule shell consists of gelatin and titanium dioxide. The capsule is printed with edible blue pharmaceutical ink which is made of FD&amp;C Blue #2 aluminum lake, propylene glycol, shellac and titanium dioxide.</p>
<p>THIS MEDICATION GUIDE HAS BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_23407622-DC7A-4B51-A137-E817CFCDC4CA"></a><a name="section-22.2"></a><p></p>
<h2>APPENDIX to Medication Guide on Ribavirin Capsules</h2>
<p class="First"><span class="Bold">[Note: In addition to REBETOL®<span class="Sup">2</span> (ribavirin) Capsules, Schering Corporation also markets REBETRON®<span class="Sup">3</span>. REBETRON is a copackaged combination therapy containing REBETOL (ribavirin, USP) and INTRON A (interferon alfa-2b, recombinant) Injection. REBETRON has medication guides that provide information on the combination use of REBETOL (ribavirin, USP) and INTRON A. This Appendix provides medication guide information on ribavirin capsules taken together with INTRON A that corresponds to information in the medication guides for REBETRON.]</span></p>
<p>Read this Appendix carefully before you begin taking ribavirin capsules together with INTRON A, and each time you refill your prescription in case there is new information. This summary does not tell you everything about ribavirin capsules taken together with INTRON A. Your health care provider is the best source of information about these medicines. After reading this Appendix, talk with your health care provider if you have any questions about this treatment.</p>
<p><span class="Underline"><span class="Bold">What is the most important information I should know about ribavirin capsules taken together with INTRON A?</span></span></p>
<ul>
<li>
<span class="Bold">Ribavirin capsules taken together with INTRON A may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of an unborn child. Therefore, if you are pregnant, you must not take therapy of ribavirin capsules taken together with INTRON A.</span> If you could become pregnant, you must not become pregnant during therapy and for six months after you have stopped therapy. During this time you must use two forms of birth control, and you must have pregnancy tests that show that you are not pregnant.<br>Female sexual partners of male patients being treated with ribavirin capsules must not become pregnant during treatment and for six months after treatment has stopped. Therefore, two forms of birth control must be used during this time.<br>If you or a female sexual partner becomes pregnant, you should tell your health care provider. There is a Ribavirin Pregnancy Registry that collects information about pregnancy outcomes in female patients and female partners of male patients exposed to ribavirin. You or your health care provider are encouraged to contact the Ribavirin Pregnancy Registry at 1-800-593-2214.</li>
<li>
<span class="Bold">Treatment with ribavirin capsules and INTRON A products can cause a dangerous drop in your blood cell counts.</span><br>Ribavirin capsules taken together with INTRON A can cause <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, which is a decrease in the number of red blood cells. This can be dangerous, especially if you have heart or breathing problems. Tell your health care provider before taking ribavirin capsules together with INTRON A if you have ever had any of these problems. Your health care provider should check your red blood cell count before starting therapy and often during the first 4 weeks of therapy. Your red blood cell count may be checked more often if you have heart or breathing problems.</li>
<li>
<span class="Bold">Ribavirin capsules taken together with INTRON A</span> can cause a dangerous drop in the number of cells that help fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which might cause you to have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>
<span class="Bold">Serious mental problems: Ribavirin capsules taken together with INTRON A may cause or worsen mood or behavioral problems.</span><br>These can include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (getting easily upset) and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (feeling low, feeling bad about yourself). Some patients think about hurting or killing themselves or other people, and some have killed themselves (<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>) or hurt themselves or others. If you experience any of these thoughts or symptoms you should tell your healthcare provider right away. See “<span class="Underline"><span class="Bold">What are the possible side effects of ribavirin capsules taken together with INTRON A??</span></span> for important information on signs of mental problems.</li>
<li>
<span class="Bold">You should not take ribavirin capsules alone to treat your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span> Ribavirin capsules should be used only in combination with interferon alfa-2b (INTRON A) for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<p><span class="Underline"><span class="Bold">What is therapy of ribavirin capsules taken together with INTRON A?</span></span></p>
<p><span class="Bold">Ribavirin capsules taken together with INTRON A is a treatment for some people who have <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. It consists of two separate medicines, ribavirin capsules and INTRON A Injection (interferon), used in combination. INTRON A helps the body’s immune system fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The antiviral drug ribavirin is made by Sandoz Inc. It is not known how ribavirin capsules and INTRON A work together to fight <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Ribavirin capsules should not be used alone to treat <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p><span class="Bold">It is not known if treatment with ribavirin capsules taken together with INTRON A will cure <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or prevent cirrhosis, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, or liver cancer that can be caused by <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. It is not known if treatment with ribavirin capsules taken together with INTRON A will prevent you from infecting another person with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus.</span></p>
<p>You should use therapy of ribavirin capsules taken together with INTRON A only if you have never been treated or your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C has returned after interferon therapy.</p>
<p><span class="Underline"><span class="Bold">Who should not take ribavirin capsules together with INTRON A?</span></span></p>
<p><span class="Bold">Do not use these medicines if:</span></p>
<ul>
<li>You are a female and you are pregnant or plan to become pregnant at any time during your treatment with ribavirin capsules taken together with INTRON A or during the 6 months after your treatment has ended.</li>
<li>You are a male patient with a female sexual partner who is pregnant or plans to become pregnant at any time while you are being treated during treatment with ribavirin capsules taken together with INTRON A or during the 6 months after your treatment has ended. <span class="Bold">Please see “<span class="Underline">What is the most important information I should know about ribavirin capsules taken together with INTRON A??</span> at the beginning of this Appendix.</span>
</li>
<li>You are breastfeeding. Ribavirin capsules and INTRON A products may pass through your milk and harm your baby. Talk with your health care provider about whether you should stop breast-feeding.</li>
<li>You have <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span> (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> caused by cells in your body attacking each other) because treatment with ribavirin capsules and INTRON A can make this kind of liver problem worse.</li>
<li>You are allergic to any of the ingredients in ribavirin capsules or INTRON A Injection, or to any alpha interferon. (See ingredients listed at the end of this Appendix.)</li>
</ul>
<p>Tell your health care provider before starting therapy of ribavirin capsules taken together with INTRON A if you have any of the following medical conditions or other serious medical problems: </p>
<ul>
<li>
<span class="Bold">mental health problems, such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</span> Ribavirin capsules taken together with INTRON A may make them worse. Tell your health care provider if you are being treated for a mental illness or had treatment in the past for any mental problems, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> is loss of contact with reality, such as hearing voices or seeing things that are not there.</li>
<li>
<span class="Bold">high blood pressure, other heart problems, or have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span> The medicines in the therapy of ribavirin capsules taken together with INTRON A may worsen heart problems. Patients who have had certain heart problems should not take the therapy of ribavirin capsules together with INTRON A.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span>,</span> including <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (low red blood cell count), <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> (Mediterranean <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), and sickle-cell <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Ribavirin capsules taken together with INTRON A can reduce the number of red blood cells you have. This may make you feel dizzy or weak and could worsen any heart problems you might have.</li>
<li>
<span class="Bold">kidney problems.</span> If your kidneys do not work well, you may get worse side effects from ribavirin capsules taken together with INTRON A and need a dose adjustment.</li>
<li>
<span class="Bold">liver problems</span> (other than <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>)</li>
<li>
<span class="Bold">organ transplant,</span> and are taking medicine that keeps your body from rejecting your transplant (suppresses your immune system)</li>
<li>
<span class="Bold">thyroid disease.</span> Ribavirin capsules taken together with INTRON A may make your thyroid disease worse or harder to treat. Ribavirin capsules taken together with INTRON A may be stopped if you develop thyroid abnormalities that cannot be controlled by medication.</li>
<li>
<span class="Bold">lung problems.</span> Ribavirin/Interferon alfa-2b therapy can cause breathing problems or worsen breathing problems you already have.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> or drug abuse or addiction</span></li>
<li><span class="Bold">cancer</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus or human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV), </span>the virus that causes AIDS.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span> Ribavirin capsules taken together with INTRON A may make your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> worse or harder to treat.</li>
<li><span class="Bold">past interferon treatment for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that did not work for you.</span></li>
</ul>
<p><span class="Underline"><span class="Bold">How should I take ribavirin capsules together with INTRON A?</span></span></p>
<ul>
<li>Your health care provider has determined the correct doses of ribavirin capsules and INTRON A. Your doses of ribavirin capsules and INTRON A may be lowered if you have side effects.</li>
<li><span class="Bold">Under no circumstance should ribavirin capsules be opened, crushed, or broken.</span></li>
</ul>
<p>The recommended doses of INTRON A Injection and ribavirin capsules for patients 18 years of age and older are shown in the table below.</p>
<a name="ID_0387C4E9-A52A-43E3-B527-34C1126FB241"></a><table border="single" frame="box" width="441.000">
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom">
<p class="First"><span class="Bold">If your</span></p>
<p><span class="Bold">weight is:</span></p>
</td>
<td class="Toprule" align="left" valign="bottom">
<p class="First"><span class="Bold">Take this many</span></p>
<p><span class="Bold">ribavirin capsules</span></p>
<p><span class="Bold">each day:</span></p>
</td>
<td class="Toprule" align="left" valign="bottom">
<p class="First"><span class="Bold">Inject this amount</span></p>
<p><span class="Bold">of INTRON A under</span></p>
<p><span class="Bold">your skin</span></p>
<span class="Bold">(subcutaneously)</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom">
<p class="First">165 pounds</p>
<p>or less</p>
</td>
<td align="left" valign="bottom">
<p class="First">2 capsules in</p>
<p> the AM</p>
<p>3 capsules in</p>
 the PM</td>
<td align="left" valign="bottom">
<p class="First">3 million</p>
<p> international units</p>
<p>3 times a week</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">
<p class="First">More than</p>
<p>165 pounds</p>
</td>
<td class="Botrule" align="left" valign="bottom">
<p class="First">3 capsules in</p>
<p> the AM</p>
<p>3 capsules in</p>
 the PM</td>
<td class="Botrule" align="left" valign="bottom">
<p class="First">3 million</p>
<p> international units</p>
<p>3 times a week</p>
</td>
</tr>
</tbody>
</table>
<ul>
<li>You can take your ribavirin capsules with or without food, but you should take it the same way every day.</li>
<li>It is important to follow your dosing schedule and your health care provider’s instructions on how to take your medicines.</li>
<li>Take the medicines for as long as they are prescribed, and do not take more than the recommended doses.</li>
<li>If you miss a dose of ribavirin capsules, take the missed dose as soon as possible during the same day. If an entire day has gone by, check with your health care provider about what to do. Do not double the next dose.</li>
<li>If you miss a dose of INTRON A, take the missed dose as soon as possible during the same day or on the next day, and continue your regular dosing schedule. If several days go by without taking INTRON A, check with your health care provider about what to do. Do not double the next dose.</li>
<li>Tell your health care provider if you are taking or planning to take other prescription or non-prescription medicines, including vitamin and mineral supplements and herbal medicines.</li>
</ul>
<p>Instructions on how to inject INTRON A are at the end of this Appendix.</p>
<p><span class="Underline"><span class="Bold">What should I avoid while taking ribavirin capsules together with INTRON A?</span></span></p>
<ul><li>
<span class="Bold">Pregnancy:</span> If you or your sexual partner becomes pregnant, tell your health care provider right away. (See “<span class="Underline"><span class="Bold">What is the most important information I should know about therapy with ribavirin capsules taken together with INTRON A??</span></span> at the beginning of this Appendix.) Talk with your health care provider about how to avoid pregnancy.</li></ul>
<p>If you or your sexual partner becomes pregnant while being treated with ribavirin capsules taken together with INTRON A or during the 6 months after treatment ends, you must report the pregnancy to your health care provider right away. Your <span class="Italics">health care provider</span> should call the Ribavirin Pregnancy Registry toll-free at 1-800-593-2214. Your health care provider will be asked to give follow-up information about the pregnancy. Any information about your pregnancy that is reported about you will be confidential.</p>
<ul>
<li>Breastfeeding. The medicine may pass through your milk and harm the baby.</li>
<li>Drinking alcohol, including beer, wine and liquor because this may make your liver disease worse.</li>
<li>Do not inject yourself with INTRON A if it is discolored or contains particles.</li>
<li>Taking any medicines other than those prescribed or approved by your health care provider </li>
<li>Ask your health care provider if there are other things you should avoid, in addition to alcohol (beer, wine, liquor), prescription and nonprescription drugs, and alternative medications (herbal medicine).</li>
</ul>
<p><span class="Underline"><span class="Bold">What are the possible side effects of ribavirin capsules taken together with INTRON A?</span></span></p>
<p><span class="Bold">Harm to unborn children.</span> Ribavirin capsules taken together with INTRON A can harm your unborn child. It can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and may kill your unborn child. (For more details, see “<span class="Underline"><span class="Bold">What is the most important information I should know about ribavirin capsules taken together with INTRON A??</span></span> at the beginning of this Appendix.)</p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>.</span> Ribavirin capsules taken together with INTRON A causes <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (a reduction in the number of red blood cells you have) which can be dangerous, especially if you have heart, or breathing problems. Tell your health care provider right away if you feel tired, have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>. These may be signs of low red blood counts.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>.</span> INTRON A therapy may lower your white blood cell count, making it easier for you to get serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. You must have your blood tested regularly during treatment to check for this problem.</li>
<li>
<span class="Bold">Mental Problems.</span> Tell your health care provider if you have ever had any mental illness, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (loss of contact with reality such as hearing voices or seeing things that are not there). Also, tell your health care provider if you are taking any medications for these problems. <span class="Bold">Tell your health care provider right away if you have the following:</span>
</li>
<li><span class="Bold">Start to feel unusually sad or have <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> spells</span></li>
<li><span class="Bold">Lose interest in your usual activities</span></li>
<li><span class="Bold">Have changes in your normal sleep patterns</span></li>
<li><span class="Bold">Become more <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span> than usual</span></li>
<li><span class="Bold">Lose your appetite</span></li>
<li><span class="Bold">Become unusually tired</span></li>
<li><span class="Bold">Have trouble concentrating</span></li>
<li><span class="Bold">Withdraw from family and friends</span></li>
<li><span class="Bold">Have thoughts about hurting yourself or others.</span></li>
</ul>
<p><span class="Bold">Tell your health care provider right away if you have any of the following symptoms. They may be signs of a serious side effect:</span></p>
<ul>
<li><span class="Bold">trouble breathing, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></span></li>
<li><span class="Bold">severe stomach or lower <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (bowel movements). These may appear to be black and tarry.</span></li>
<li><span class="Bold">high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
<li><span class="Bold">decreased vision</span></li>
</ul>
<p><span class="Underline"><span class="Bold">What are the most common side effects of ribavirin capsules taken together with INTRON A?</span></span></p>
<ul>
<li>
<span class="Bold">“Flu-like? symptoms.</span> These include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, feeling very tired (<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. These get better as treatment continues. You can reduce some of these flu-like symptoms by injecting your INTRON A about 2 hours before bedtime. Some health care providers suggest taking non-prescription <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> reducers, such as acetaminophen or ibuprofen before taking INTRON A. This may be helpful to prevent or relieve the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</li>
<li><span class="Bold">Feeling tired</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair thinning</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and appetite loss</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span></li>
<li><span class="Bold">Trouble breathing</span></li>
<li><span class="Bold">Trouble with your vision</span></li>
<li><span class="Bold">Trouble sleeping at night</span></li>
</ul>
<p>This summary does not include all possible side effects of combination therapy. You should talk to your health care provider, if you do not feel well while taking ribavirin capsules and INTRON A. Your health care provider can give you more information about managing your side effects.</p>
<p><span class="Underline"><span class="Bold">What should I know about the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus?</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is a disease caused by a virus that infects the liver. This liver <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> becomes a continuing (chronic) condition in most patients. Patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may develop cirrhosis, liver cancer, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. The virus is spread from one person to another by contact with the infected person’s blood. You should talk to your health care provider about ways to prevent you from infecting others.</p>
<p><span class="Underline"><span class="Bold">How do I Inject INTRON A?</span></span></p>
<ul>
<li>When you have been trained to do it properly. If you have any questions, contact your health care provider before injecting INTRON A.</li>
<li>Use the sterile technique taught by your health care provider. Use disposable needles after each use, and throw them away properly as directed by your health care provider, nurse, or pharmacist.</li>
<li>If someone else gives you your injection, that person should be trained in the use of sterile technique and how to avoid an accidental needle stick.</li>
</ul>
<p><span class="Underline"><span class="Bold">Preparing the INTRON A Dose</span></span></p>
<p><span class="Bold">IMPORTANT:</span> Before each use, the liquid in the vial (small bottle) should be clear, colorless to light yellow, and without particles. <span class="Bold">Do not use the medicine if you see particles or the color is not correct. </span>Call your doctor, nurse, or pharmacist to find out what to do if this happens.</p>
<ol>
<li>Check the date printed on the INTRON A carton to make sure that the expiration date has not passed.</li>
<li>Wash your hands well and remove the protective plastic cap from the top of the INTRON A vial.</li>
<li>Remove the protective plastic wrapper from the syringe provided <span class="Bold">(Figure A).</span> The safety sleeve should be tight against the flange for use and moved over the needle only when ready for disposal, as instructed in step 6.<br><div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-02.jpg"></div>
<br><span class="Bold">Figure A</span>
</li>
<li>Clean the rubber stopper on the top of the INTRON A vial with an alcohol swab.</li>
<li>Remove the protective cap from the syringe needle. Ensure safety sleeve is pushed firmly against the syringe flange so that the needle is fully exposed. Fill the syringe with air by pulling the plunger to the level that represents your correct dose <span class="Bold">(Figure B).</span><br><div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-03.jpg"></div>
<br><span class="Bold">Figure B</span>
</li>
<li>Hold the INTRON A vial upright without touching the cleaned top of the vial with your hands <span class="Bold">(Figure C).</span><br><div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-04.jpg"></div>
<br><span class="Bold">Figure C</span>
</li>
<li>Insert the needle into the vial containing the INTRON A solution and inject the air into the vial <span class="Bold">(Figure D).</span><br><div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-05.jpg"></div>
<br><span class="Bold">Figure D</span>
</li>
<li>Turn vial and syringe upside down in one hand. Be sure tip of needle is in the INTRON A solution. Your other hand will be free to move the plunger. Pull back on plunger slowly to draw the correct dose into syringe <span class="Bold">(Figure E).</span><br><div class="Figure"><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-06.jpg"></div>
<br><span class="Bold">Figure E</span><br>
</li>
<li>Remove the needle from the vial <span class="Bold">(Figure F)</span> and check for air bubbles in the syringe. If you see any bubbles, tap the syringe gently. Then, with the needle pointing up, push the plunger slowly until the bubbles disappear.<br><div class="Figure"><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-07.jpg"></div>
<br><span class="Bold">Figure F</span><br>
</li>
<li>Replace the needle cap. If the solution is <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, warm the syringe between your hands. Lay the syringe down on a flat surface so that needle does not touch anything.</li>
</ol>
<p><span class="Underline"><span class="Bold">Subcutaneous (under the skin) Injection</span></span></p>
<ol>
<li>Select the site for injection <br>• The best sites for injection are tissues with a layer of fat between skin and muscle, such as the <br>• thigh<br>• outer surface of the upper arm<br>• abdomen (stomach area), except the navel (belly button) or waistline <br>• If you are very thin, use only the thigh or outer surface of the arm for injection.<br>• Do not inject INTRON A solution in the same place repeatedly. Change your injection site in a regular pattern.<br>Use an alcohol swab to cleanse the skin where the injection is to be made. Wait for area to dry.<br><div class="Figure"><img alt="Figure 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-08.jpg"></div>
</li>
<li>Remove the cap from the needle. Ensure the safety sleeve is pushed firmly against the syringe flange so that the needle is fully exposed. Hold the syringe with one hand, as you would hold a pencil. With the other hand, pinch approximately a 2-inch fold of loose skin.</li>
<li>With a quick dart-like motion, push the needle about 1/4 inch into the pinched skin at an angle of 45° to 90°.<br>After the needle is in, remove hand used to pinch skin and use it to hold syringe barrel. Pull back the plunger very slightly with one hand. If blood comes into the syringe, the needle has entered a blood vessel. Do not inject. Withdraw and discard needle and syringe as instructed in step 6 below. Prepare a new syringe and inject at a new site. (Follow steps 2 and 3.)<br><div class="Figure"><img alt="Figure 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-09.jpg"></div>
</li>
<li>If blood does not appear in the syringe, gently push the plunger all the way down.</li>
<li>Hold an alcohol swab near the needle and pull the needle straight out of the skin. Press the alcohol swab over the injection site for several seconds. Do not massage (rub) the injection site. If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover the area with an adhesive bandage.</li>
<li>After use, firmly grasp the safety sleeve and pull over the exposed needle until you hear a click, and the green stripe on the safety sleeve covers the red stripe on the needle.<br><div class="Figure"><img alt="Figure 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-10.jpg"></div>
</li>
<li>Use disposable syringe only once to ensure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of syringe and needle. Dispose of syringe and needle as directed.<br>Your health care professional should tell you about the proper handling and disposal of all syringes and needles and the importance of not reusing any syringes or needles.<br>Your health care professional should give you a container for throwing away used needles and syringes. Throw away the full container according to directions provided by your doctor.</li>
<li>After 2 hours, check injection site for signs of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>. If there are signs of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, contact your doctor.</li>
</ol>
<p><span class="Underline"><span class="Bold">HOW TO USE YOUR INTRON A Multidose Pen</span></span></p>
<p><span class="Italics">When you are ready to give your injection prepare your pen as follows</span><span class="Bold"><span class="Italics">(NOTE: Boldface print indicates ACTION STEPS):</span></span></p>
<ol>
<li>
<span class="Bold">First check that you have the correct INTRON A multidose pen as prescribed by your health care provider,</span> (i.e. the six doses of 3 MIU INTRON A multidose pen which have a <span class="Bold">brown</span> push button and a <span class="Bold">brown</span> color coding strip).</li>
<li>
<span class="Bold">Pull off the cap of the pen and disinfect the rubber membrane</span> (see Diagram C) <span class="Bold">with one alcohol wipe.</span><br><div class="Figure"><img alt="Figure 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-11.jpg"></div>
<br><span class="Bold">Diagram C</span><br>
</li>
<li>
<span class="Bold">Remove the protective tab from the Novofine<span class="Sup">4</span> needle.</span> Note that the rear portion of the needle is revealed once the protective tab is removed (see Diagram D).<br><div class="Figure"><img alt="Figure 12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-12.jpg"></div>
<br><span class="Bold">Diagram D</span>
</li>
<li>
<span class="Bold">Gently push the Novofine<span class="Sup">4</span> needle onto the pen as shown in Diagram E.</span> (Notice that the rear portion of the needle described in Step 3 will pierce through the rubber membrane that you disinfected previously.) <span class="Bold">Now screw the needle onto the INTRON A multidose pen securely by turning it in a clockwise direction </span>(see Diagram F).<br><div class="Figure"><img alt="Figure 13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-13.jpg"></div>
<br><span class="Bold">Diagram E</span><br><div class="Figure"><img alt="Figure 14" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-14.jpg"></div>
<br><span class="Bold">Diagram F</span>
</li>
<li>
<span class="Bold">First, pull off the outer needle cap</span> (Diagram G). <span class="Bold">Then, pull off the inner needle cap carefully, bearing in mind that the needle will now be exposed</span> (Diagram H). Keep the outer needle cap for later use.<br>The pen is now ready to use. Since a small amount of air may collect in the needle and reservoir during storage, the next step is to remove any air bubbles.<br><div class="Figure"><img alt="Figure 15" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-15.jpg"></div>
<br><span class="Bold">Diagram G</span><br><div class="Figure"><img alt="Figure 16" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-16.jpg"></div>
<br><span class="Bold">Diagram H</span>
</li>
<li><span class="Bold">Hold the INTRON A multidose pen with the needle point upwards.</span></li>
<li>
<span class="Bold">Tap the reservoir with your finger so that any air bubbles rise to the top of the reservoir, just below the needle</span> (Diagram I).<br><div class="Figure"><img alt="Figure 17" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-17.jpg"></div>
<br><span class="Bold">Diagram I</span>
</li>
<li>
<span class="Bold">Hold the pen by the barrel and turn the reservoir in the direction as indicated by the arrow in Diagram J (clockwise) until you feel it click.</span><br><div class="Figure"><img alt="Figure 18" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-18.jpg"></div>
<br><span class="Bold">Diagram J</span>
</li>
<li>
<span class="Bold">Keeping the pen pointing upwards, press the push button up fully and see if a drop of INTRON A solution appears at the needle tip</span> (notice the drop at the tip of needle in Diagram K).<br><div class="Figure"><img alt="Figure 19" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-19.jpg"></div>
<br><span class="Bold">Diagram K</span>
</li>
<li>
<span class="Bold">If no drop appears then repeat Steps 7, 8, and 9 until a drop appears at the needle tip.</span> Note: Some air may still remain in the pen, but this is not important as you have removed the air from the needle and the dose will be accurate.</li>
<li>
<span class="Bold">Replace the INTRON A multidose pen cap with the ‘triangle’ opposite the dosage indicator as seen in Diagram L.<br></span>The pen is now ready to set the dose. For the next step hold the pen in the middle of the barrel. This will allow the push button to move freely, ensuring that the correct dose is set.<br><div class="Figure"><img alt="Figure 20" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-20.jpg"></div>
<br><span class="Bold">Diagram L</span>
</li>
<li>
<span class="Bold">To set the required dose, hold the pen horizontally by the barrel with one hand. With the other hand, turn the cap in a clockwise direction indicated by the arrow in Diagram M.</span> You will observe the push button rising, indicating the dose set. To set a 3 MIU dose, turn the cap 2 full turns (10 clicks) = 3.0 MIU.<br>Note: If your health care provider has prescribed a dose other than 3 MIU, the correct dose can be set by turning the cap as many times as indicated as follows: <br>1 full turn (5 clicks) = 1.5 MIU<br>3 full turns (15 clicks) = 4.5 MIU<br>4 full turns (20 clicks) = 6.0 MIU<br>The push button scale will show you the dose set (see Diagram N). At that point check that you have the correct dose.<br><div class="Figure"><img alt="Figure 21" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-21.jpg"></div>
<br><span class="Bold">Diagram M</span><br><div class="Figure"><img alt="Figure 22" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-22.jpg"></div>
<br><span class="Bold">Diagram N</span>
</li>
<li>
<span class="Bold">After each complete turn make sure that the triangle is opposite the dosage indicator</span> (see Diagram O). If you have set a wrong dose, simply turn the cap back (counter-clockwise) as far as you can until the push button is fully home and start again. Once the correct dose is set, you are ready to give the injection.<br><div class="Figure"><img alt="Figure 23" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-23.jpg"></div>
<br><span class="Bold">Diagram O</span>
</li>
<li><span class="Bold">To give the injection, remove the pen cap from the needle. With one hand, pinch a 2-inch fold of loose skin.</span></li>
<li>
<span class="Bold">With your other hand, pick up the pen and hold it as you would a pencil. Insert the needle into the pinched skin at an angle of approximately 45°</span> (see Diagram P) <span class="Bold">then press the push button down fully.<br>If blood comes into the pen, do not inject. Withdraw the needle and consult your physician or pharmacist.</span><br><div class="Figure"><img alt="Figure 24" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-24.jpg"></div>
<br><span class="Bold">Diagram P</span>
</li>
<li><span class="Bold">Leave the needle in place for a few seconds, while holding down the push button, to allow the INTRON A Solution to distribute under the skin.</span></li>
<li><span class="Bold">Slowly release the push button, then remove the needle.</span></li>
<li>
<span class="Bold">Carefully replace the </span><span class="Bold"><span class="Italics">outer</span></span><span class="Bold">needle cap using a scooping motion</span> (See Diagram Q).<br><div class="Figure"><img alt="Figure 25" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-25.jpg"></div>
<br><span class="Bold">Diagram Q</span>
</li>
<li>
<span class="Bold">Completely unscrew the needle assembly using a counterclockwise turning motion as show in Diagram R. Then carefully lift it off the pen and discard the capped needle </span>(see Diagram S).<br><div class="Figure"><img alt="Figure 26" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-26.jpg"></div>
<br><span class="Bold">Diagram R</span><br><div class="Figure"><img alt="Figure 27" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-27.jpg"></div>
<br><span class="Bold">Diagram S</span>
</li>
<li>
<span class="Bold">Replace the pen cap with the triangle once again opposite the dosage indicator as shown in Diagram T.</span><br><div class="Figure"><img alt="Figure 28" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=ribavirin-28.jpg"></div>
<br><span class="Bold">Diagram T</span>
</li>
</ol>
<p><span class="Bold">Instructional leaflet and video are available through your healthcare provider.</span></p>
<p><span class="Underline"><span class="Bold">How do I store my medications?</span></span></p>
<p><span class="Underline"><span class="Bold">STORAGE OF RIBAVIRIN CAPSULES</span></span></p>
<p><span class="Bold">Store ribavirin capsules at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</span></p>
<p><span class="Underline"><span class="Bold">STORAGE OF INTRON A INJECTION VIAL AND MULTIDOSE PEN</span></span></p>
<p><span class="Bold">INTRON A Injection vial and multidose pen should be stored in the refrigerator between 36° and 46°F (2° and 8°C), not in the freezer.</span></p>
<p><span class="Underline"><span class="Bold">General advice about prescription medicines</span></span></p>
<p>Do not use ribavirin capsules or INTRON A for conditions for which they were not prescribed. If you have any concern about therapy of taking ribavirin capsules together with INTRON A, ask your health care provider. Your health care provider or pharmacist can give you information about ribavirin capules taken together with INTRON A that was written for health care professionals. Do not give these medicines to other people, even if they have the same condition you have.</p>
<p><span class="Bold">Ingredients:</span> Ribavirin capsules contain ribavirin and the inactive ingredients croscarmellose sodium, hypromellose, magnesium stearate, mannitol, and povidone. The capsule shell consists of gelatin and titanium dioxide. The capsule is printed with edible blue pharmaceutical ink which is made of FD&amp;C Blue #2 aluminum lake, propylene glycol, shellac and titanium dioxide.</p>
<p><span class="Underline">THIS MEDICATION GUIDE HAS BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION.</span></p>
<ol>
<li>INTRON® A is a registered trademark of Schering Corporation.</li>
<li>REBETOL® is a registered trademark of Schering Corporation.</li>
<li>REBETRON® is a registered trademark of Schering Corporation.</li>
<li>Novofine is a registered trademark of Novo Nordisk.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_01A9EC79-8E07-4D86-8BE4-E0AA6F414E95"></a><a name="section-23"></a><p></p>
<h1></h1>
<p class="First">Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<h1>Label Image for 200mg</h1>
<div class="Figure"><img alt="Label Image for 200mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b8b0c65-e466-4662-9e85-5a253d31ebe8&amp;name=Ribavirin%20200mg(Sandoz).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIBAVIRIN 		
					</strong><br><span class="contentTableReg">ribavirin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0781(NDC:0781-2043)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIBAVIRIN</strong> (RIBAVIRIN) </td>
<td class="formItem">RIBAVIRIN</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RIBAVIRIN;200;mg;GG;608</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0781-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076192</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cbb7cff7-62dd-4bb5-aee5-4202eb730940</div>
<div>Set id: 3b8b0c65-e466-4662-9e85-5a253d31ebe8</div>
<div>Version: 1</div>
<div>Effective Time: 20100608</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
